The following files are required for me to teach students appearing fo

The following files are required for me to teach students appearing for the INI SS CET CVTS which is a single best answer multiple choice question examination. Generate 2 files from chapter 60 1. High yield notes from each chapter for teaching with probable questions. 2. 20 MCQs from chapter 60 in the INI CET SS format single best answer, can have a paragraph question. Do include image questions as well, images to be added in the PDF itself, with attribute from where it has been taken, source can be the internet as well. Make sure that the PDF has all 20 questions.

Reading File

Running Command

cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/daytona/workspace/attachments/43826880-c2b8-4a74-848d-7076ac1a6dd0/Chapter_60_PDF_pages_168-183.pdf' with pdfplumber.open(pdf_path) as pdf: print(f'Total pages: {len(pdf.pages)}') for i, page in enumerate(pdf.pages): text = page.extract_text() print(f'--- PAGE {i+1} ---') print(text[:3000] if text else '[NO TEXT]') print() " 2>&1 | head -400

Running Command

cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/daytona/workspace/attachments/43826880-c2b8-4a74-848d-7076ac1a6dd0/Chapter_60_PDF_pages_168-183.pdf' full_text = [] with pdfplumber.open(pdf_path) as pdf: for i, page in enumerate(pdf.pages): text = page.extract_text() if text: full_text.append(f'=== PAGE {i+1} ===\n{text}') print('\n'.join(full_text)) " 2>&1 | tail -n +1 | head -600

Running Command

cd /home/daytona/workspace && python3 -c " import pdfplumber pdf_path = '/home/daytona/workspace/attachments/43826880-c2b8-4a74-848d-7076ac1a6dd0/Chapter_60_PDF_pages_168-183.pdf' full_text = [] with pdfplumber.open(pdf_path) as pdf: for i, page in enumerate(pdf.pages[11:], start=12): text = page.extract_text() if text: full_text.append(f'=== PAGE {i} ===\n{text}') print('\n'.join(full_text)) " 2>&1

I now have the complete chapter text. Let me also extract the images from the PDF and search for relevant clinical images for the MCQ document.

Running Command

cd /home/daytona/workspace && python3 -c " import fitz # PyMuPDF import os pdf_path = '/home/daytona/workspace/attachments/43826880-c2b8-4a74-848d-7076ac1a6dd0/Chapter_60_PDF_pages_168-183.pdf' output_dir = '/home/daytona/workspace/ch60_images' os.makedirs(output_dir, exist_ok=True) doc = fitz.open(pdf_path) img_count = 0 for page_num in range(len(doc)): page = doc[page_num] images = page.get_images() for img_idx, img in enumerate(images): xref = img[0] base_image = doc.extract_image(xref) img_bytes = base_image['image'] img_ext = base_image['ext'] img_filename = f'{output_dir}/page{page_num+1}_img{img_idx+1}.{img_ext}' with open(img_filename, 'wb') as f: f.write(img_bytes) print(f'Saved: {img_filename} ({len(img_bytes)} bytes)') img_count += 1 print(f'Total images extracted: {img_count}') " 2>&1

Running Command

cd /home/daytona/workspace && python3 -c " import pdfplumber import os pdf_path = '/home/daytona/workspace/attachments/43826880-c2b8-4a74-848d-7076ac1a6dd0/Chapter_60_PDF_pages_168-183.pdf' output_dir = '/home/daytona/workspace/ch60_images' os.makedirs(output_dir, exist_ok=True) with pdfplumber.open(pdf_path) as pdf: for page_num, page in enumerate(pdf.pages): images = page.images print(f'Page {page_num+1}: {len(images)} image(s)') for i, img in enumerate(images): print(f' img {i+1}: x0={img[\"x0\"]:.1f}, y0={img[\"y0\"]:.1f}, width={img[\"width\"]:.1f}, height={img[\"height\"]:.1f}') " 2>&1

Now I have all the content. Let me create both files simultaneously using parallel subagents.

Running Command

mkdir -p /home/daytona/workspace/ch60_output && ls /home/daytona/workspace/ch60_output

Running Command

cat > /home/daytona/workspace/ch60_output/generate_teaching_notes.py << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import mm, cm from reportlab.lib import colors from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, PageBreak, ListFlowable, ListItem, KeepTogether) from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY import os OUTPUT_PATH = '/home/daytona/workspace/ch60_output/Ch60_High_Yield_Teaching_Notes.pdf' doc = SimpleDocTemplate( OUTPUT_PATH, pagesize=A4, rightMargin=2*cm, leftMargin=2*cm, topMargin=2*cm, bottomMargin=2*cm ) styles = getSampleStyleSheet() # Custom styles title_style = ParagraphStyle('ChapterTitle', parent=styles['Heading1'], fontSize=20, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a3a5c'), spaceAfter=6, spaceBefore=6, alignment=TA_CENTER) subtitle_style = ParagraphStyle('SubTitle', parent=styles['Normal'], fontSize=11, fontName='Helvetica', textColor=colors.HexColor('#555555'), spaceAfter=10, alignment=TA_CENTER) h1_style = ParagraphStyle('H1', parent=styles['Heading1'], fontSize=14, fontName='Helvetica-Bold', textColor=colors.white, spaceBefore=14, spaceAfter=6, backColor=colors.HexColor('#1a3a5c'), leftIndent=-6, rightIndent=-6, borderPad=5) h2_style = ParagraphStyle('H2', parent=styles['Heading2'], fontSize=12, fontName='Helvetica-Bold', textColor=colors.HexColor('#c0392b'), spaceBefore=10, spaceAfter=4, borderPad=2) h3_style = ParagraphStyle('H3', parent=styles['Heading3'], fontSize=11, fontName='Helvetica-Bold', textColor=colors.HexColor('#2980b9'), spaceBefore=8, spaceAfter=3) body_style = ParagraphStyle('Body', parent=styles['Normal'], fontSize=10, fontName='Helvetica', textColor=colors.HexColor('#222222'), spaceAfter=5, spaceBefore=2, leading=14, alignment=TA_JUSTIFY) bullet_style = ParagraphStyle('Bullet', parent=styles['Normal'], fontSize=10, fontName='Helvetica', textColor=colors.HexColor('#222222'), spaceAfter=3, spaceBefore=1, leading=13, leftIndent=14, bulletIndent=4) highlight_style = ParagraphStyle('Highlight', parent=styles['Normal'], fontSize=10, fontName='Helvetica', textColor=colors.HexColor('#7b0000'), backColor=colors.HexColor('#fff3f3'), spaceAfter=4, spaceBefore=4, leading=14, leftIndent=6, rightIndent=6, borderPad=5) exam_style = ParagraphStyle('ExamTip', parent=styles['Normal'], fontSize=10, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a5c1a'), backColor=colors.HexColor('#efffef'), spaceAfter=4, spaceBefore=4, leading=14, leftIndent=6, rightIndent=6, borderPad=5) memory_style = ParagraphStyle('MemoryAid', parent=styles['Normal'], fontSize=10, fontName='Helvetica-Oblique', textColor=colors.HexColor('#5a0070'), backColor=colors.HexColor('#f9f0ff'), spaceAfter=4, spaceBefore=4, leading=14, leftIndent=6, rightIndent=6, borderPad=5) table_header_style = ParagraphStyle('TableHeader', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=colors.white, alignment=TA_CENTER) table_cell_style = ParagraphStyle('TableCell', parent=styles['Normal'], fontSize=9, fontName='Helvetica', textColor=colors.HexColor('#222222')) def make_table(data, col_widths=None): if col_widths is None: col_widths = [doc.width / len(data[0])] * len(data[0]) t = Table(data, colWidths=col_widths, repeatRows=1) t.setStyle(TableStyle([ ('BACKGROUND', (0, 0), (-1, 0), colors.HexColor('#1a3a5c')), ('TEXTCOLOR', (0, 0), (-1, 0), colors.white), ('FONTNAME', (0, 0), (-1, 0), 'Helvetica-Bold'), ('FONTSIZE', (0, 0), (-1, 0), 9), ('ROWBACKGROUNDS', (0, 1), (-1, -1), [colors.white, colors.HexColor('#eef4fb')]), ('FONTNAME', (0, 1), (-1, -1), 'Helvetica'), ('FONTSIZE', (0, 1), (-1, -1), 9), ('ALIGN', (0, 0), (-1, -1), 'CENTER'), ('VALIGN', (0, 0), (-1, -1), 'MIDDLE'), ('GRID', (0, 0), (-1, -1), 0.5, colors.HexColor('#bbbbbb')), ('TOPPADDING', (0, 0), (-1, -1), 4), ('BOTTOMPADDING', (0, 0), (-1, -1), 4), ('LEFTPADDING', (0, 0), (-1, -1), 6), ('RIGHTPADDING', (0, 0), (-1, -1), 6), ])) return t def B(text): return f'{text}' def I(text): return f'{text}' def bullet(text): return Paragraph(f'• {text}', bullet_style) def sub_bullet(text): return Paragraph(f' – {text}', bullet_style) story = [] # ============================================================ # TITLE PAGE BLOCK # ============================================================ story.append(Spacer(1, 0.5*cm)) story.append(Paragraph("INI SS CET – CVTS", subtitle_style)) story.append(Paragraph("Chapter 60", subtitle_style)) story.append(Paragraph("Transcatheter Treatment of Mitral and Tricuspid Valve Disease", title_style)) story.append(Paragraph("High-Yield Teaching Notes for INI SS CET Preparation", subtitle_style)) story.append(HRFlowable(width="100%", thickness=2, color=colors.HexColor('#1a3a5c'), spaceAfter=14)) # ============================================================ # SECTION 1: INTRODUCTION & EPIDEMIOLOGY # ============================================================ story.append(Paragraph("1. INTRODUCTION & DISEASE OVERVIEW", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph(B("Mitral Valve Disease"), h2_style)) story.append(bullet("Mitral valve most common valve disease; MVP is the most common MV disease in the United States")) story.append(bullet("Severe MR correction recommended: symptomatic patients OR LV dysfunction (LVEF ≤60% or LVESD ≥40 mm)")) story.append(bullet(B("Primary MR") + " = structural defect in MV apparatus → surgical repair superior to replacement")) story.append(bullet(B("Secondary (Functional) MR") + " = LV/LA dilation distorts annulus; replacement more durable than repair")) story.append(bullet("Up to 50% of patients with operative indications for MR avoided surgery due to comorbidities/frailty")) story.append(Paragraph(B("Tricuspid Valve Disease"), h2_style)) story.append(bullet("TR correction recommended with concurrent left-sided valve surgery; isolated TR surgery considered for symptomatic TR")) story.append(bullet("Most TR is secondary (functional); isolated tricuspid surgery historically has high mortality (up to 25%)")) story.append(bullet("Etiology of secondary TR: LV disease → pulmonary hypertension → RV overload → annular dilation → malcoaptation")) story.append(bullet("Tricuspid annulus dilates preferentially along anterior and posterior leaflets; septal leaflet size relatively constant")) story.append(bullet(B("Primary causes of TR:") + " infective endocarditis, congenital, lead-induced (pacemaker/ICD)")) story.append(bullet(B("Rheumatic fever") + " is the most common cause of tricuspid stenosis")) story.append(Paragraph("★ EXAM TIP: The tricuspid annulus dilates along the AP and PP commissures – malcoaptation is between anteroposterior and posteroseptal commissures", exam_style)) story.append(Spacer(1, 0.3*cm)) # ============================================================ # SECTION 2: TRANSCATHETER MITRAL VALVE REPAIR (TMVr) # ============================================================ story.append(Paragraph("2. TRANSCATHETER MITRAL VALVE REPAIR (TMVr)", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("2A. MitraClip (TEER – Transcatheter Edge-to-Edge Repair)", h2_style)) story.append(bullet(B("Device:") + " Abbott; cobalt-chromium arms covered with polyester")) story.append(bullet(B("Technique:") + " Reproduces Alfieri 'edge-to-edge' stitch (described 1990s) – opposes free edges of A1/P2 leaflets creating a double-orifice valve")) story.append(bullet(B("Access:") + " Transvenous transseptal approach under general anesthesia with TEE guidance")) story.append(bullet("4th-generation device; >1 clip placed in ~50% of cases")) story.append(bullet(B("Only commercially available TMVr device in USA (as of 2021)") + "; applicable in both primary and secondary MR")) story.append(Paragraph(B("PASCAL System (Edwards Lifesciences)"), h3_style)) story.append(bullet("CE mark approval in Europe; not yet FDA approved as of 2021")) story.append(bullet("Features: Nitinol frame, central spacer, independent leaflet grasping, broader paddles")) story.append(bullet("CLASP IID/IIF Pivotal Trial: first head-to-head MitraClip vs. PASCAL trial (NCT03706822)")) story.append(Paragraph("2B. Key Clinical Trials – Landmark", h2_style)) trial_data = [ [Paragraph(B("Trial"), table_header_style), Paragraph(B("N"), table_header_style), Paragraph(B("Population"), table_header_style), Paragraph(B("Key Result"), table_header_style)], [Paragraph("EVEREST II", table_cell_style), Paragraph("258\n(178 clip / 80 surgery)", table_cell_style), Paragraph("73% primary MR; all ≥3+ MR; high/prohibitive surgical risk", table_cell_style), Paragraph("Primary endpoint (freedom from death/surgery/≥3+MR):\n55% MitraClip vs 73% surgery (P=.007)\n30-day AE: 15% vs 48%\n5-yr survival: similar", table_cell_style)], [Paragraph("COAPT", table_cell_style), Paragraph("614", table_cell_style), Paragraph("Secondary MR + HF; EF 20-50%", table_cell_style), Paragraph("MitraClip + GDMT vs GDMT alone\nRehospitalization: 35.8% vs 67.9%\nMortality at 2yr: 29.1% vs 46.1%\n→ Significant BENEFIT", table_cell_style)], [Paragraph("MITRA-FR", table_cell_style), Paragraph("304", table_cell_style), Paragraph("Severe secondary MR + HF", table_cell_style), Paragraph("MitraClip + medical vs medical alone\nNo difference in HF rehospitalization\nor death at 1 and 2 years\n→ NO BENEFIT", table_cell_style)], ] story.append(make_table(trial_data, col_widths=[3.5*cm, 2.5*cm, 5.5*cm, 6.5*cm])) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph(B("Why do COAPT and MITRA-FR differ?"), h3_style)) story.append(bullet("COAPT enrolled " + B("disproportionately severe") + " MR patients (EROA high relative to LVEDV)")) story.append(bullet("MITRA-FR enrolled " + B("proportionately severe") + " MR patients (EROA proportional to dilated LV)")) story.append(bullet("Patient selection for TEER in secondary MR requires careful clinical, imaging, and hemodynamic assessment")) story.append(Paragraph("FDA approved MitraClip for secondary MR (COAPT criteria):", h3_style)) story.append(bullet("EF between 20% and 50%")) story.append(bullet("Moderate-to-severe or worse MR despite GDMT")) story.append(bullet("LVESD < 7.0 cm")) story.append(bullet("Pulmonary artery systolic pressure < 70 mmHg")) story.append(Paragraph("★ EXAM TIP: COAPT = Benefit (disproportionate MR). MITRA-FR = No benefit (proportionate MR).\nMemory: COAPT COuld AP To (treat) disproportionate MR.", exam_style)) story.append(Paragraph("2C. Real-World Outcomes (TVT Registry)", h2_style)) outcomes_data = [ [Paragraph(B("Endpoint"), table_header_style), Paragraph(B("Result"), table_header_style)], [Paragraph("Total TEER procedures worldwide", table_cell_style), Paragraph(">100,000", table_cell_style)], [Paragraph("In-hospital mortality", table_cell_style), Paragraph("~2%", table_cell_style)], [Paragraph("Stroke rate", table_cell_style), Paragraph("<1%", table_cell_style)], [Paragraph("Conversion to MV surgery", table_cell_style), Paragraph("<5 in 1000", table_cell_style)], [Paragraph("30-day mortality", table_cell_style), Paragraph("~4.5%", table_cell_style)], [Paragraph("MR reduction to <moderate at 30 days", table_cell_style), Paragraph(">90%", table_cell_style)], [Paragraph("MV gradient >5 mmHg post-TEER", table_cell_style), Paragraph("~25% of patients", table_cell_style)], [Paragraph("1-year mortality", table_cell_style), Paragraph("~25%", table_cell_style)], ] story.append(make_table(outcomes_data, col_widths=[9*cm, 9*cm])) story.append(Spacer(1, 0.2*cm)) story.append(bullet("FDA approved MitraClip for primary MR at prohibitive surgical risk: " + B("2014"))) story.append(bullet("FDA approved for secondary MR: " + B("2020"))) story.append(bullet("TEER use in USA increased 10-fold: ~1000 cases (2014) → >10,000 cases (2019)")) story.append(Paragraph("2D. Other TMVr Devices", h2_style)) story.append(bullet(B("Cardioband (Edwards Lifesciences):") + " Transcatheter annuloplasty; polyester sleeve on posterior annulus; CE mark approval (Europe), no FDA approval")) story.append(bullet(B("NeoChord DS1000:") + " Transapical artificial chordal implantation; European CE mark; under pivotal trial (ReChord, NCT02803957)")) story.append(bullet(B("Harpoon (Edwards Lifesciences):") + " Transapical chordal implantation; European approval")) story.append(bullet(B("Mitra-Spacer, Half Moon, Mistral:") + " Annular cinching/spacer devices; limited human experience")) story.append(bullet(B("Atrial Functional MR:") + " AF → dilated LA → mitral annular dilation with normal LV; target for annuloplasty devices")) story.append(Paragraph("2E. Future of TMVr – Key Trials", h2_style)) future_data = [ [Paragraph(B("Trial"), table_header_style), Paragraph(B("Population"), table_header_style), Paragraph(B("Comparison"), table_header_style)], [Paragraph("MITRA-HR (Europe)", table_cell_style), Paragraph("High-risk degenerative MR", table_cell_style), Paragraph("MitraClip vs surgical repair", table_cell_style)], [Paragraph("REPAIR-MR (USA)", table_cell_style), Paragraph("Intermediate-risk >75 yr degenerative MR", table_cell_style), Paragraph("MitraClip vs surgical repair", table_cell_style)], [Paragraph("PRIMARY MR (NIH)", table_cell_style), Paragraph("All surgical risk levels >65 yr", table_cell_style), Paragraph("TEER vs surgical repair (superiority)", table_cell_style)], [Paragraph("MATTERHORN", table_cell_style), Paragraph("High-risk functional MR", table_cell_style), Paragraph("MitraClip vs surgical repair/replacement", table_cell_style)], [Paragraph("EVOLVE-MR", table_cell_style), Paragraph("Moderate functional MR", table_cell_style), Paragraph("MitraClip vs GDMT", table_cell_style)], [Paragraph("Cardioband ACTIVE", table_cell_style), Paragraph("Functional MR", table_cell_style), Paragraph("Cardioband annuloplasty vs GDMT", table_cell_style)], ] story.append(make_table(future_data, col_widths=[5*cm, 5.5*cm, 7.5*cm])) story.append(Spacer(1, 0.3*cm)) # ============================================================ # SECTION 3: TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) # ============================================================ story.append(Paragraph("3. TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR)", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("3A. Valve-in-Valve (ViV) and Valve-in-Ring (ViR)", h2_style)) story.append(bullet("Surgical MVR now performed with bioprosthetic valves in >75% of cases")) story.append(bullet("Reoperative MV surgery carries 10-15% mortality → driving TMVR ViV")) story.append(bullet("FDA approved TMVR for degenerated valves using balloon-expandable transcatheter valves: " + B("2017"))) story.append(bullet(B("TVT Registry (2014-2020):") + " >3000 ViV procedures; 30-day mortality 5%; 1-year mortality 23%")) story.append(bullet("Most common complications: bleeding 13%, AF 5%, MV reintervention 2%, stroke 2%")) story.append(bullet("MR reduced to ≤moderate in >99%")) story.append(bullet("Valve-in-ring mortality is nearly double that of valve-in-valve")) story.append(bullet("Trend from transapical → transseptal approach")) story.append(Paragraph("3B. Valve-in-Mitral Annular Calcification (MAC)", h2_style)) story.append(bullet("Severe MAC: greatly increases surgical risk (stroke, AV disruption, circumflex artery injury, LV rupture)")) story.append(bullet("Two key limitations: " + B("LVOTO") + " and " + B("valve embolization"))) story.append(bullet(B("Hybrid approach:") + " Mid-portion of anterior leaflet resected, balloon-expandable valve implanted under direct/thoracoscopic vision, limited sutures; limited septal myomectomy to reduce LVOTO")) story.append(Paragraph("3C. Native Transcatheter Mitral Valve Replacement Devices", h2_style)) devices_data = [ [Paragraph(B("Device"), table_header_style), Paragraph(B("Manufacturer"), table_header_style), Paragraph(B("Approach"), table_header_style), Paragraph(B("Key Features / Trial"), table_header_style)], [Paragraph("Tendyne", table_cell_style), Paragraph("Abbott", table_cell_style), Paragraph("Transapical", table_cell_style), Paragraph("Self-expanding nitinol; trileaflet porcine; epicardial tether\nCE mark Jan 2020; SUMMIT trial", table_cell_style)], [Paragraph("Intrepid", table_cell_style), Paragraph("Medtronic", table_cell_style), Paragraph("Transapical/ Transseptal", table_cell_style), Paragraph("Outer oversized frame anchors; inner bovine pericardial valve\nAPOLLO trial (NCT03242642)", table_cell_style)], [Paragraph("EVOQUE", table_cell_style), Paragraph("Edwards Lifesciences", table_cell_style), Paragraph("Transfemoral Transseptal", table_cell_style), Paragraph("Trileaflet bovine pericardial; nitinol frame; intra-annular sealing skirt\nMISCEND trial (NCT02718001)\nAlso used for tricuspid replacement", table_cell_style)], [Paragraph("Tiara", table_cell_style), Paragraph("Neovasc", table_cell_style), Paragraph("Transapical", table_cell_style), Paragraph("Early feasibility", table_cell_style)], [Paragraph("AltaValve", table_cell_style), Paragraph("4C Medical", table_cell_style), Paragraph("Transapical", table_cell_style), Paragraph("Early feasibility", table_cell_style)], [Paragraph("Cardiovalve", table_cell_style), Paragraph("Cardiovalve", table_cell_style), Paragraph("Transseptal", table_cell_style), Paragraph("Early feasibility", table_cell_style)], [Paragraph("SAPIEN M3", table_cell_style), Paragraph("Edwards", table_cell_style), Paragraph("Transseptal", table_cell_style), Paragraph("Early feasibility", table_cell_style)], [Paragraph("HighLife", table_cell_style), Paragraph("Highlife SAS", table_cell_style), Paragraph("Combined", table_cell_style), Paragraph("Early feasibility", table_cell_style)], ] story.append(make_table(devices_data, col_widths=[3*cm, 3*cm, 3.5*cm, 8.5*cm])) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("★ EXAM TIP: Tendyne = Abbott, transapical, epicardial tether. Intrepid = Medtronic, outer-inner frame design. EVOQUE = Edwards, used for BOTH mitral AND tricuspid.", exam_style)) # ============================================================ # SECTION 4: TRICUSPID VALVE DISEASE # ============================================================ story.append(Paragraph("4. TRANSCATHETER TRICUSPID VALVE INTERVENTIONS", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("4A. Surgical Background", h2_style)) story.append(bullet("Isolated tricuspid valve surgery: historically " + B("up to 25% operative mortality"))) story.append(bullet("Improving outcomes in modern era with better patient selection")) story.append(bullet("Transcatheter approaches emerged due to high reoperative risk")) story.append(Paragraph("4B. Etiology of TR", h2_style)) tr_etiol_data = [ [Paragraph(B("Type"), table_header_style), Paragraph(B("Etiology"), table_header_style), Paragraph(B("Mechanism"), table_header_style)], [Paragraph("Secondary (most common)", table_cell_style), Paragraph("Left-sided heart disease, pulmonary HTN", table_cell_style), Paragraph("RV overload → annular dilation → leaflet tethering and malcoaptation", table_cell_style)], [Paragraph("Atrial functional TR (Type I)", table_cell_style), Paragraph("Atrial fibrillation", table_cell_style), Paragraph("LA dilation → annular dilation with normal LV", table_cell_style)], [Paragraph("Lead-induced", table_cell_style), Paragraph("Pacemaker/ICD leads", table_cell_style), Paragraph("Traumatic leaflet damage", table_cell_style)], [Paragraph("Primary", table_cell_style), Paragraph("IE, congenital, rheumatic, carcinoid", table_cell_style), Paragraph("Direct valve pathology", table_cell_style)], [Paragraph("Stenosis", table_cell_style), Paragraph("Rheumatic fever (most common)", table_cell_style), Paragraph("Leaflet thickening/fusion", table_cell_style)], ] story.append(make_table(tr_etiol_data, col_widths=[4*cm, 5*cm, 9*cm])) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("4C. Preprocedural Evaluation for Transcatheter TV Interventions", h2_style)) story.append(bullet(B("Echocardiography:") + " Primary imaging modality; device sizing, leaflet anatomy, EROA, regurgitation jet")) story.append(bullet(B("CT scan:") + " Detailed tricuspid apparatus morphology, landing zone, anchoring sites, right coronary artery, papillary muscles, IVC size")) story.append(bullet(B("Cardiac MRI:") + " RV volumes, tricuspid regurgitant volume and EROA quantification")) story.append(bullet("Tricuspid malcoaptation primarily at anteroposterior and posteroseptal commissures")) story.append(Paragraph("4D. Transcatheter TV Therapies – Classification", h2_style)) story.append(bullet(B("Leaflet Coaptation:") + " MitraClip, PASCAL, FORMA, Mistral, CroiValve")) story.append(bullet(B("Annuloplasty:") + " Cardioband, TriAlign, TriCinch, TRI-RING")) story.append(bullet(B("Orthotopic Replacement:") + " EVOQUE, Intrepid, SAPIEN valves (ViV/ViR), Trisol, GATE, Lux-Valve")) story.append(bullet(B("Heterotopic (Caval) Replacement:") + " SAPIEN XT/3 in IVC/SVC, TricValve, Tricento")) story.append(Paragraph("5. LEAFLET COAPTATION DEVICES (Tricuspid)", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("5A. MitraClip / TriClip for Tricuspid Valve", h2_style)) story.append(bullet("Off-label MitraClip use on tricuspid valve: extensive early experience")) story.append(bullet("Challenges vs mitral: larger annulus, thinner and more fragile leaflets")) story.append(bullet("Clips can approximate anterior + septal leaflets → " + B("bicuspid valve"))) story.append(bullet("All 3 leaflets clipped → " + B("clover technique") + " (trifoliate configuration)")) story.append(bullet("TriClip (Abbott): dedicated tricuspid version of MitraClip")) story.append(bullet(B("TRILUMINATE trial (NCT03227757):") + " TriClip evaluation; 6-month outcomes showed effective TR reduction at 1 year with low mortality")) story.append(Paragraph("5B. PASCAL (Edwards Lifesciences)", h2_style)) story.append(bullet("First used for TV repair in 2018 (Fam et al.)")) story.append(bullet("Features: central spacer, independent grasping, nitinol")) story.append(bullet(B("CLASP TR Early Feasibility Study (NCT03745313)"))) story.append(Paragraph("5C. FORMA (Edwards Lifesciences)", h2_style)) story.append(bullet("Foam-filled polymer balloon spacer + rail anchored in RV with 6-pronged nitinol anchor")) story.append(bullet("Reduces regurgitant orifice area: leaflets coaptate against the spacer")) story.append(bullet("50% reduction in EROA at 30 days; failed to show sustained improvement at 1 year; 7/25 patients still had severe TR")) story.append(bullet(B("Device discontinued") + " – trials halted")) story.append(bullet("Trials: NCT02471807 and SPACER (NCT02787408)")) story.append(Paragraph("5D. Mistral (Mitralix)", h2_style)) story.append(bullet("Spiral-shaped device: rotated to grasp chordae tendineae and pull diverged leaflets together")) story.append(bullet("7 first-in-human cases; TR reduction and improved RV function at 30 days")) story.append(bullet("Trials: MATTERS (NCT04071652) and MATTERS II (NCT04073979)")) story.append(Paragraph("6. ANNULOPLASTY DEVICES (Tricuspid)", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("6A. TriAlign (Mitralign)", h2_style)) story.append(bullet("Transcatheter suture annuloplasty mimicking the " + B("Kay procedure") + " (bicuspidization)")) story.append(bullet("Two pledgets at anteroposterior and septoposterior commissure → sutured together")) story.append(bullet("SCOUT trial: 80% technical success; NYHA improvement; pledget dehiscence issue reported")) story.append(bullet("SCOUT II trial ongoing")) story.append(Paragraph("6B. TriCinch (4Tech Cardio)", h2_style)) story.append(bullet("Coil anchored to TV annulus + Dacron band connected to self-expanding nitinol stent in IVC")) story.append(bullet("Tethering force applied to downsize TV annulus")) story.append(bullet("PREVENT trial: 25% anchor detachment → design modified to nitinol-coil anchor")) story.append(bullet("Further trials terminated by sponsor")) story.append(Paragraph("6C. Cardioband (Edwards Lifesciences) – Tricuspid", h2_style)) story.append(bullet("Dacron sleeve with screws on contraction wire → cinched into TV annulus")) story.append(bullet("CE approval April 2018 after TRI-REPAIR trial (NCT02981953)")) story.append(bullet("Ongoing: TriBAND (Europe) and Edwards Cardioband EFS (NCT03382457, USA)")) story.append(Paragraph("6D. TRI-RING (Cardiac Implants)", h2_style)) story.append(bullet("Two-stage device: flexible ring anchored → 90 days tissue healing → cinched down to reduce annular diameter")) story.append(bullet("Clinical trial ongoing (NCT03700918)")) story.append(Paragraph("7. ORTHOTOPIC TRICUSPID VALVE REPLACEMENT", h1_style)) story.append(Spacer(1, 0.2*cm)) ortho_data = [ [Paragraph(B("Device"), table_header_style), Paragraph(B("Company"), table_header_style), Paragraph(B("Key Features"), table_header_style), Paragraph(B("Trial"), table_header_style)], [Paragraph("EVOQUE", table_cell_style), Paragraph("Edwards Lifesciences", table_cell_style), Paragraph("Trileaflet bovine pericardial; nitinol frame; intra-annular sealing skirt; ventricular anchors capture leaflets+chordae; transfemoral", table_cell_style), Paragraph("TRISCEND II (pivotal)", table_cell_style)], [Paragraph("Intrepid TTVR", table_cell_style), Paragraph("Medtronic", table_cell_style), Paragraph("Self-expanding nitinol; outer+inner frame; bovine pericardial", table_cell_style), Paragraph("NCT04433065", table_cell_style)], [Paragraph("SAPIEN ViV/ViR", table_cell_style), Paragraph("Edwards", table_cell_style), Paragraph("Balloon-expandable; for degenerated bioprosthesis; SAPIEN XT → SAPIEN 3; First reported 2011 (Van Garsse)", table_cell_style), Paragraph("Multiple registries; multicenter", table_cell_style)], [Paragraph("Trisol", table_cell_style), Paragraph("Trisol Medical", table_cell_style), Paragraph("Single dome-shaped bovine pericardial leaflet on nitinol stent; functions as two leaflets; early feasibility (NCT04905017)", table_cell_style), Paragraph("NCT04905017", table_cell_style)], [Paragraph("GATE", table_cell_style), Paragraph("NaviGate", table_cell_style), Paragraph("Orthotopic; animal model testing", table_cell_style), Paragraph("Preclinical", table_cell_style)], ] story.append(make_table(ortho_data, col_widths=[3*cm, 3.5*cm, 7*cm, 4.5*cm])) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("★ EXAM TIP: EVOQUE = Edwards = both mitral and tricuspid replacement. TRISCEND II = pivotal trial for EVOQUE tricuspid.", exam_style)) story.append(Paragraph("8. HETEROTOPIC (CAVAL) TRICUSPID VALVE REPLACEMENT", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(bullet("Concept: place valve in IVC (and/or SVC) to reduce systemic venous reflux from TR")) story.append(bullet("Goal: reduce hepatic/renal vein peak systolic pressures")) story.append(bullet(B("SAPIEN XT (TRICAVAL trial, Europe):") + " Terminated due to valve dislocation and stent migration complications")) story.append(bullet(B("HOVER trial (SAPIEN valves in IVC):") + " NCT02339974 – ongoing; benefits yet to be proven")) story.append(bullet(B("TricValve (P&F, Vienna):") + " Two self-expandable bovine pericardial PTFE-lined valves in SVC + IVC")) story.append(bullet("TRICUS STUDY (NCT03723239, NCT04141137): TricValve safety/efficacy")) story.append(bullet(B("Tricento (New Valve Technology):") + " IVC anchor device; implemented in humans; no clinical trials yet")) story.append(bullet("Multicenter study (25 patients): 8% 30-day mortality; technically feasible; low complication rate")) story.append(Paragraph("★ EXAM TIP: CAVAL VALVE IMPLANTATION (CAVI) = heterotopic approach to TR.\nTricValve has 2 valves (SVC + IVC). Tricento anchors in IVC.", exam_style)) # ============================================================ # SECTION 9: HIGH-YIELD COMPARISON TABLES # ============================================================ story.append(Paragraph("9. HIGH-YIELD COMPARISON SUMMARY TABLES", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("Mitral vs Tricuspid TEER – Key Differences", h2_style)) diff_data = [ [Paragraph(B("Feature"), table_header_style), Paragraph(B("Mitral TEER"), table_header_style), Paragraph(B("Tricuspid TEER"), table_header_style)], [Paragraph("Annulus size", table_cell_style), Paragraph("Smaller", table_cell_style), Paragraph("Larger", table_cell_style)], [Paragraph("Leaflet thickness", table_cell_style), Paragraph("Thicker, more robust", table_cell_style), Paragraph("Thinner, more fragile", table_cell_style)], [Paragraph("Primary device", table_cell_style), Paragraph("MitraClip (Abbott)", table_cell_style), Paragraph("TriClip (Abbott) – off-label/TRILUMINATE", table_cell_style)], [Paragraph("Clip configuration options", table_cell_style), Paragraph("Single/double MitraClip", table_cell_style), Paragraph("Bicuspid (A+S) or Clover (all 3 leaflets)", table_cell_style)], [Paragraph("Evidence base", table_cell_style), Paragraph("Strong (EVEREST II, COAPT, MITRA-FR)", table_cell_style), Paragraph("Emerging (TRILUMINATE)", table_cell_style)], [Paragraph("FDA approval", table_cell_style), Paragraph("Yes (primary 2014; secondary 2020)", table_cell_style), Paragraph("No dedicated approval as of 2021", table_cell_style)], ] story.append(make_table(diff_data, col_widths=[5*cm, 5.5*cm, 7.5*cm])) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph("Transcatheter Approaches to TR – Mechanism Summary", h2_style)) mech_data = [ [Paragraph(B("Approach"), table_header_style), Paragraph(B("Devices"), table_header_style), Paragraph(B("Mechanism"), table_header_style)], [Paragraph("Leaflet coaptation", table_cell_style), Paragraph("MitraClip/TriClip, PASCAL, FORMA, Mistral", table_cell_style), Paragraph("Approximate valve leaflets to reduce regurgitation", table_cell_style)], [Paragraph("Annuloplasty", table_cell_style), Paragraph("Cardioband, TriAlign, TriCinch, TRI-RING", table_cell_style), Paragraph("Reduce annular diameter to restore coaptation", table_cell_style)], [Paragraph("Orthotopic replacement", table_cell_style), Paragraph("EVOQUE, Intrepid, SAPIEN (ViV/ViR), Trisol", table_cell_style), Paragraph("Replace native valve in anatomic position", table_cell_style)], [Paragraph("Heterotopic (caval)", table_cell_style), Paragraph("SAPIEN XT, TricValve, Tricento", table_cell_style), Paragraph("Valves in SVC/IVC to reduce venous reflux from TR", table_cell_style)], ] story.append(make_table(mech_data, col_widths=[4.5*cm, 6*cm, 7.5*cm])) story.append(Spacer(1, 0.2*cm)) # ============================================================ # SECTION 10: PROBABLE EXAM QUESTIONS # ============================================================ story.append(Paragraph("10. PROBABLE EXAM QUESTIONS & HIGH-YIELD POINTS", h1_style)) story.append(Spacer(1, 0.2*cm)) pq_data = [ [Paragraph(B("#"), table_header_style), Paragraph(B("Topic"), table_header_style), Paragraph(B("Key Exam Point"), table_header_style)], [Paragraph("1", table_cell_style), Paragraph("Alfieri technique", table_cell_style), Paragraph("Surgical 'edge-to-edge' technique; single stitch opposing free edges of anterior and posterior MV leaflets → double orifice", table_cell_style)], [Paragraph("2", table_cell_style), Paragraph("MitraClip approach", table_cell_style), Paragraph("Transvenous TRANSSEPTAL approach under general anesthesia with TEE guidance", table_cell_style)], [Paragraph("3", table_cell_style), Paragraph("EVEREST II primary endpoint", table_cell_style), Paragraph("Composite: freedom from death + MV surgery + ≥3+ MR. MitraClip 55% vs Surgery 73% (P=0.007) – surgery superior for primary endpoint, but lower 30-day AE with MitraClip", table_cell_style)], [Paragraph("4", table_cell_style), Paragraph("COAPT vs MITRA-FR", table_cell_style), Paragraph("COAPT = disproportionate MR → benefit. MITRA-FR = proportionate MR → no benefit. Key: EROA vs LVEDV ratio", table_cell_style)], [Paragraph("5", table_cell_style), Paragraph("COAPT inclusion criteria (FDA-approved)", table_cell_style), Paragraph("EF 20-50%; mod-severe or worse MR on GDMT; LVESD <7.0 cm; PA systolic <70 mmHg", table_cell_style)], [Paragraph("6", table_cell_style), Paragraph("Tendyne device", table_cell_style), Paragraph("Abbott; transapical; self-expanding nitinol; porcine valve; epicardial polyethylene tether; CE mark Jan 2020; SUMMIT trial", table_cell_style)], [Paragraph("7", table_cell_style), Paragraph("Most common complication ViV TMVR", table_cell_style), Paragraph("Bleeding (13%), then AF (5%); 30-day mortality 5%, 1-year mortality 23%", table_cell_style)], [Paragraph("8", table_cell_style), Paragraph("MAC and TMVR complications", table_cell_style), Paragraph("LVOTO and valve embolization; managed by hybrid approach (anterior leaflet resection + direct implantation)", table_cell_style)], [Paragraph("9", table_cell_style), Paragraph("TV anatomy landmarks", table_cell_style), Paragraph("3 leaflets: Anterior (A), Posterior (P), Septal (S). AV node = blue spot near coronary sinus/tendon of Todaro", table_cell_style)], [Paragraph("10", table_cell_style), Paragraph("Most common cause of TR", table_cell_style), Paragraph("Secondary (functional); left-sided heart disease → pulmonary HTN → RV overload → annular dilation", table_cell_style)], [Paragraph("11", table_cell_style), Paragraph("Most common cause of tricuspid stenosis", table_cell_style), Paragraph("Rheumatic fever", table_cell_style)], [Paragraph("12", table_cell_style), Paragraph("TriAlign / Kay procedure analogy", table_cell_style), Paragraph("Kay bicuspidization: TriAlign mimics Kay by plicating posterior leaflet with 2 pledgets at AP and SP commissures", table_cell_style)], [Paragraph("13", table_cell_style), Paragraph("FORMA device outcome", table_cell_style), Paragraph("Discontinued – failed to show sustained benefit; spacer (balloon) in TV; 7/25 still had severe TR at 1 year", table_cell_style)], [Paragraph("14", table_cell_style), Paragraph("TricValve device", table_cell_style), Paragraph("TWO valves in SVC + IVC (heterotopic); TRICUS STUDY ongoing", table_cell_style)], [Paragraph("15", table_cell_style), Paragraph("PASCAL vs MitraClip", table_cell_style), Paragraph("PASCAL: central spacer + independent leaflet grasping + broader paddles; CLASP IID/IIF = first head-to-head trial", table_cell_style)], [Paragraph("16", table_cell_style), Paragraph("Atrial functional MR", table_cell_style), Paragraph("AF → dilated LA → annular dilation with NORMAL LV; distinct from typical secondary MR", table_cell_style)], [Paragraph("17", table_cell_style), Paragraph("TriCinch PREVENT trial issue", table_cell_style), Paragraph("25% anchor detachment → design changed from screw tip to nitinol-coil anchor", table_cell_style)], [Paragraph("18", table_cell_style), Paragraph("Cardioband (TV) regulatory status", table_cell_style), Paragraph("CE approval April 2018 after TRI-REPAIR trial; US: early feasibility (NCT03382457)", table_cell_style)], [Paragraph("19", table_cell_style), Paragraph("Imaging for TV preprocedural planning", table_cell_style), Paragraph("Echo (primary), CT (landing zone/anatomy), CMR (RV volumes + TR quantification)", table_cell_style)], [Paragraph("20", table_cell_style), Paragraph("NeoChord system", table_cell_style), Paragraph("Transapical artificial chordal implantation; CE mark; ReChord trial (NCT02803957) vs surgical repair", table_cell_style)], ] story.append(make_table(pq_data, col_widths=[0.7*cm, 4.3*cm, 13*cm])) story.append(Spacer(1, 0.2*cm)) # ============================================================ # SECTION 11: MEMORY AIDS # ============================================================ story.append(Paragraph("11. MEMORY AIDS & MNEMONICS", h1_style)) story.append(Spacer(1, 0.2*cm)) story.append(Paragraph('"COAPT vs MITRA-FR" – Remember the patient profiles:', h3_style)) story.append(Paragraph('COAPT = C = "Can treat" disproportionate MR (EROA high, LV not too dilated)\nMITRA-FR = "More proportionate" MR = No benefit', memory_style)) story.append(Paragraph('"Alfieri → MitraClip" – The origin:', h3_style)) story.append(Paragraph('Alfieri described edge-to-edge technique in EARLY 1990s\nMitraClip = mechanical version of the Alfieri stitch = double-orifice valve', memory_style)) story.append(Paragraph('"Tendyne mnemonic":', h3_style)) story.append(Paragraph('TENDYNE: Tether + Dense porcine valve + Yes it\'s Abbott + Nitinol expanding\nDelivered Transapically; Nitinol frame; European CE mark 2020', memory_style)) story.append(Paragraph('"TV Annuloplasty Devices" – TTCT:', h3_style)) story.append(Paragraph('TriAlign (Kay procedure analogy)\nTriCinch (IVC stent tethering)\nCardioband Tricuspid (Dacron sleeve/screws)\nTRI-RING (Two-stage cinching)', memory_style)) story.append(Paragraph('"Heterotopic = CAVAL VALVE IMPLANTATION (CAVI)":', h3_style)) story.append(Paragraph('TricValve = 2 valves (SVC + IVC)\nTricento = 1 valve (IVC only)\nSAPIEN XT = TRICAVAL trial (terminated) / HOVER trial (ongoing)', memory_style)) story.append(Paragraph('"FORMA was FORMA-tted for failure":', h3_style)) story.append(Paragraph('FORMA = Foam spacer in RV. Failed to sustain TR reduction beyond 30 days. Device DISCONTINUED.', memory_style)) story.append(Spacer(1, 0.5*cm)) story.append(HRFlowable(width="100%", thickness=1, color=colors.HexColor('#1a3a5c'), spaceAfter=8)) story.append(Paragraph("Prepared for INI SS CET CVTS | Chapter 60: Transcatheter Treatment of Mitral and Tricuspid Valve Disease | DiMaio et al.", subtitle_style)) doc.build(story) print(f"PDF created at: {OUTPUT_PATH}") PYEOF python3 /home/daytona/workspace/ch60_output/generate_teaching_notes.py

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

continue

Picking up from where we left off - the teaching notes script had a syntax error from the < character in ReportLab XML. Let me fix and generate both files.

Running Command

cat > /home/daytona/workspace/ch60_output/generate_teaching_notes.py << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import mm, cm from reportlab.lib import colors from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, PageBreak) from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY OUTPUT_PATH = '/home/daytona/workspace/ch60_output/Ch60_High_Yield_Teaching_Notes.pdf' doc = SimpleDocTemplate( OUTPUT_PATH, pagesize=A4, rightMargin=2*cm, leftMargin=2*cm, topMargin=2*cm, bottomMargin=2*cm ) styles = getSampleStyleSheet() title_style = ParagraphStyle('CT', parent=styles['Heading1'], fontSize=18, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a3a5c'), spaceAfter=6, spaceBefore=6, alignment=TA_CENTER) subtitle_style = ParagraphStyle('ST', parent=styles['Normal'], fontSize=10, fontName='Helvetica', textColor=colors.HexColor('#555555'), spaceAfter=8, alignment=TA_CENTER) h1_style = ParagraphStyle('H1', parent=styles['Heading1'], fontSize=13, fontName='Helvetica-Bold', textColor=colors.white, spaceBefore=12, spaceAfter=4, backColor=colors.HexColor('#1a3a5c'), leftIndent=-4, rightIndent=-4, borderPad=4) h2_style = ParagraphStyle('H2', parent=styles['Heading2'], fontSize=11, fontName='Helvetica-Bold', textColor=colors.HexColor('#c0392b'), spaceBefore=8, spaceAfter=3) h3_style = ParagraphStyle('H3', parent=styles['Heading3'], fontSize=10, fontName='Helvetica-Bold', textColor=colors.HexColor('#2980b9'), spaceBefore=6, spaceAfter=2) body_style = ParagraphStyle('Body', parent=styles['Normal'], fontSize=10, fontName='Helvetica', spaceAfter=4, spaceBefore=1, leading=14, alignment=TA_JUSTIFY) bullet_style = ParagraphStyle('Bul', parent=styles['Normal'], fontSize=10, fontName='Helvetica', spaceAfter=3, spaceBefore=1, leading=13, leftIndent=14, bulletIndent=4) exam_style = ParagraphStyle('Exam', parent=styles['Normal'], fontSize=10, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a5c1a'), backColor=colors.HexColor('#efffef'), spaceAfter=4, spaceBefore=4, leading=13, leftIndent=6, rightIndent=6, borderPad=4) memory_style = ParagraphStyle('Mem', parent=styles['Normal'], fontSize=10, fontName='Helvetica-Oblique', textColor=colors.HexColor('#5a0070'), backColor=colors.HexColor('#f9f0ff'), spaceAfter=4, spaceBefore=4, leading=13, leftIndent=6, rightIndent=6, borderPad=4) th_style = ParagraphStyle('TH', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=colors.white, alignment=TA_CENTER) tc_style = ParagraphStyle('TC', parent=styles['Normal'], fontSize=9, fontName='Helvetica', textColor=colors.HexColor('#222222')) def tbl(data, cw=None): if cw is None: cw = [doc.width/len(data[0])]*len(data[0]) t = Table(data, colWidths=cw, repeatRows=1) t.setStyle(TableStyle([ ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1a3a5c')), ('TEXTCOLOR',(0,0),(-1,0),colors.white), ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'), ('FONTSIZE',(0,0),(-1,0),9), ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.white,colors.HexColor('#eef4fb')]), ('FONTNAME',(0,1),(-1,-1),'Helvetica'), ('FONTSIZE',(0,1),(-1,-1),9), ('ALIGN',(0,0),(-1,-1),'CENTER'), ('VALIGN',(0,0),(-1,-1),'MIDDLE'), ('GRID',(0,0),(-1,-1),0.5,colors.HexColor('#bbbbbb')), ('TOPPADDING',(0,0),(-1,-1),4),('BOTTOMPADDING',(0,0),(-1,-1),4), ('LEFTPADDING',(0,0),(-1,-1),5),('RIGHTPADDING',(0,0),(-1,-1),5), ])) return t def P(text, style=None): s = style or body_style return Paragraph(text, s) def bul(text): return Paragraph(f'• {text}', bullet_style) S = lambda h=0.3: Spacer(1, h*cm) HR = lambda: HRFlowable(width="100%", thickness=1, color=colors.HexColor('#1a3a5c'), spaceAfter=8) story = [] # Title story += [S(0.3), P("INI SS CET - CVTS | Chapter 60", subtitle_style), P("Transcatheter Treatment of Mitral and Tricuspid Valve Disease", title_style), P("High-Yield Teaching Notes | DiMaio, Shih, Squiers, Mack", subtitle_style), HR(), S(0.2)] # ==== SECTION 1 ==== story.append(P("1. INTRODUCTION & DISEASE EPIDEMIOLOGY", h1_style)) story.append(P("Mitral Valve Disease", h2_style)) for t in [ "Mitral valve pathology = most common valve disease; MVP = most common MV disease in the USA", "Severe MR correction: symptomatic patients OR asymptomatic with LVEF <=60% or LVESD >=40 mm", "Primary MR = structural defect of MV apparatus; surgical repair superior to replacement", "Secondary (Functional) MR = LV/LA dilation distorts annulus; replacement more durable than repair", "Up to 50% of patients with operative indications for MR avoid surgery due to frailty/comorbidities", ]: story.append(bul(t)) story.append(P("Tricuspid Valve Disease", h2_style)) for t in [ "TR correction recommended with concurrent left-sided valve surgery; isolated TR surgery for symptomatic TR", "Isolated tricuspid surgery historically carries up to 25% operative mortality", "Most TR is secondary; recs do not favour repair over replacement regardless of etiology", "Secondary TR pathway: Left-sided disease → pulmonary HTN → RV overload → annular dilation → leaflet tethering", "Tricuspid annulus dilates along anterior and posterior leaflets; septal leaflet size relatively constant", "Malcoaptation primarily at anteroposterior and posteroseptal commissures", "Atrial functional TR (Type I): AF → dilated LA → annular dilation with normal LV", "Lead-induced TR: pacemaker / ICD leads → traumatic leaflet damage", "Rheumatic fever = most common cause of tricuspid stenosis", ]: story.append(bul(t)) story.append(P("EXAM TIP: TV anatomy - 3 leaflets: Anterior (A), Posterior (P), Septal (S). AV node = blue spot near coronary sinus / tendon of Todaro.", exam_style)) story.append(S()) # ==== SECTION 2 ==== story.append(P("2. TRANSCATHETER MITRAL VALVE REPAIR (TMVr)", h1_style)) story.append(P("2A. MitraClip - Transcatheter Edge-to-Edge Repair (TEER)", h2_style)) for t in [ "Manufacturer: Abbott Vascular, Menlo Park, CA", "Mimics Alfieri technique (described early 1990s): single stitch opposing free edges of anterior + posterior MV leaflets → double-orifice valve", "Access: Transvenous, transseptal approach; general anaesthesia + TEE guidance", "Device: cobalt-chromium arms + polyester covering; now 3rd/4th generation", "More than 1 clip placed in ~50% of cases", "Only commercially available TMVr in USA as of 2021; applicable in both primary and secondary MR", ]: story.append(bul(t)) story.append(P("2B. PASCAL System (Edwards Lifesciences)", h3_style)) for t in [ "CE mark in Europe; not yet FDA-approved as of 2021", "Features: nitinol frame, central spacer, independent leaflet grasping, broader paddles", "CLASP IID/IIF Pivotal Trial (NCT03706822): first head-to-head PASCAL vs MitraClip trial", ]: story.append(bul(t)) story.append(P("2C. Landmark Clinical Trials", h2_style)) td = [ [P("Trial",th_style), P("N",th_style), P("Population",th_style), P("Key Outcome",th_style)], [P("EVEREST II",tc_style), P("258\n(178 clip/80 surg)",tc_style), P("73% primary MR; all >=3+ MR; high/prohibitive surgical risk",tc_style), P("Primary endpoint 55% clip vs 73% surgery (P=.007). 30-day AE: 15% vs 48%. 5-yr survival: similar. FDA approval for primary MR prohibitive risk.",tc_style)], [P("COAPT",tc_style), P("614",tc_style), P("Secondary MR + HF; EF 20-50%; LVESD <7.0 cm; PA systolic <70 mmHg",tc_style), P("MitraClip + GDMT vs GDMT alone. 2-yr rehospitalization: 35.8% vs 67.9%. 2-yr mortality: 29.1% vs 46.1%. SIGNIFICANT BENEFIT.",tc_style)], [P("MITRA-FR",tc_style), P("304",tc_style), P("Severe secondary MR + HF",tc_style), P("MitraClip + medical vs medical alone. No difference in HF rehospitalization or death at 1 and 2 years. NO BENEFIT.",tc_style)], ] story.append(tbl(td, cw=[3*cm,2.5*cm,5*cm,7.5*cm])) story.append(S(0.2)) story.append(P("COAPT vs MITRA-FR - Reconciliation", h3_style)) for t in [ "COAPT = disproportionately severe MR (EROA high relative to LVEDV) → greater benefit from device", "MITRA-FR = proportionately severe MR (EROA commensurate with dilated LV) → no added benefit", "Patients with disproportionate MR derive greater benefit from transcatheter vs medical optimization alone", "Patient selection for TEER in secondary MR requires nuance: clinical + imaging + hemodynamic variables + optimized GDMT", ]: story.append(bul(t)) story.append(P("FDA-Approved Inclusion Criteria for MitraClip in Secondary MR (COAPT criteria):", h3_style)) for t in ["EF between 20% and 50%", "Moderate-to-severe or worse MR despite GDMT", "LVESD < 7.0 cm", "PA systolic pressure < 70 mmHg"]: story.append(bul(t)) story.append(P("EXAM TIP: COAPT = Benefit (disproportionate MR). MITRA-FR = No benefit (proportionate MR). Key variable: EROA relative to LVEDV.", exam_style)) story.append(P("2D. Real-World Outcomes (TVT Registry)", h2_style)) od = [ [P("Endpoint",th_style), P("Result",th_style)], [P("Total TEER worldwide",tc_style), P(">100,000",tc_style)], [P("USA increase 2014-2019",tc_style), P("~1,000 → >10,000 (10-fold)",tc_style)], [P("FDA approval primary MR",tc_style), P("2014 (prohibitive surgical risk)",tc_style)], [P("FDA approval secondary MR",tc_style), P("2020",tc_style)], [P("In-hospital mortality",tc_style), P("~2%",tc_style)], [P("Stroke rate",tc_style), P("<1%",tc_style)], [P("Conversion to MV surgery",tc_style), P("<5 per 1000 cases",tc_style)], [P("30-day mortality",tc_style), P("~4.5%",tc_style)], [P("MR reduced to <mod-severe at 30 days",tc_style), P(">90%",tc_style)], [P("MV gradient >5 mmHg post-TEER",tc_style), P("~1 in 4 patients (25%)",tc_style)], [P("1-year mortality",tc_style), P("~25%",tc_style)], ] story.append(tbl(od, cw=[9*cm,9*cm])) story.append(S(0.2)) story.append(P("2E. Other TMVr Devices", h2_style)) for t in [ "Cardioband (Edwards): Polyester sleeve on posterior annulus; repositionable anchors + contraction wire; CE mark Europe; early feasibility USA (functional MR)", "NeoChord DS1000: Transapical artificial chordal implantation; CE mark (Europe); ReChord trial vs surgical repair (NCT02803957)", "Harpoon (Edwards): Transapical chordal implantation; European CE mark", "Mitra-Spacer / Half Moon / Mistral: Annular cinching/spacer devices; minimal human experience", "Atrial Functional MR: AF → dilated LA → annular dilation with NORMAL LV size/function; target for annuloplasty", ]: story.append(bul(t)) story.append(P("2F. Future TMVr Trials", h2_style)) ftd = [ [P("Trial",th_style), P("Population",th_style), P("Comparison",th_style)], [P("MITRA-HR (Europe)",tc_style), P("High-risk degenerative MR",tc_style), P("MitraClip vs surgical repair",tc_style)], [P("REPAIR-MR (USA)",tc_style), P("Intermediate-risk >75 yr degenerative MR",tc_style), P("MitraClip vs surgical repair",tc_style)], [P("PRIMARY MR (NIH)",tc_style), P("All surgical risks >65 yr",tc_style), P("TEER vs surgical repair (superiority trial)",tc_style)], [P("MATTERHORN",tc_style), P("High-risk functional MR",tc_style), P("MitraClip vs surgical repair/replacement",tc_style)], [P("EVOLVE-MR",tc_style), P("Moderate functional MR",tc_style), P("MitraClip vs GDMT",tc_style)], [P("Cardioband ACTIVE",tc_style), P("Functional MR",tc_style), P("Cardioband annuloplasty vs GDMT",tc_style)], [P("CLASP IID/IIF",tc_style), P("Degenerative or functional MR",tc_style), P("MitraClip vs PASCAL (NCT03706822)",tc_style)], ] story.append(tbl(ftd, cw=[5*cm,5.5*cm,7.5*cm])) story.append(S(0.3)) # ==== SECTION 3 ==== story.append(P("3. TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR)", h1_style)) story.append(P("3A. Valve-in-Valve (ViV) and Valve-in-Ring (ViR)", h2_style)) for t in [ "Surgical MVR now uses bioprosthetic valves in >75% of cases", "Reoperative MV surgery: 10-15% operative mortality → driving TMVR ViV", "FDA approved TMVR for degenerated valves (balloon-expandable): 2017", "TVT Registry (2014-2020): >3000 ViV; 30-day mortality 5%; 1-year mortality 23%", "Complications: bleeding 13%, AF 5%, MV reintervention 2%, stroke 2%", "MR reduced to <= moderate in >99%", "Valve-in-ring mortality nearly DOUBLE that of valve-in-valve", "Trend: transapical approach → transseptal approach (preferred)", ]: story.append(bul(t)) story.append(P("3B. Valve-in-MAC (Mitral Annular Calcification)", h2_style)) for t in [ "Severe MAC greatly increases surgical risk: stroke, AV disruption, circumflex artery injury, LV rupture", "Two transcatheter limitations: LVOT obstruction and valve embolization", "Hybrid approach: Resect mid-portion of anterior MV leaflet + balloon-expandable valve implanted under direct/thoracoscopic vision + limited sutures", "Limited septal myomectomy may further reduce LVOTO risk", ]: story.append(bul(t)) story.append(P("3C. Native TMVR Devices", h2_style)) nd = [ [P("Device",th_style), P("Company",th_style), P("Approach",th_style), P("Key Features / Trial",th_style)], [P("Tendyne",tc_style), P("Abbott",tc_style), P("Transapical",tc_style), P("Self-expanding nitinol; trileaflet porcine valve; epicardial polyethylene tether. CE mark Jan 2020. SUMMIT trial (NCT03433274).",tc_style)], [P("Intrepid",tc_style), P("Medtronic",tc_style), P("Transapical / Transseptal",tc_style), P("Outer oversized frame anchors onto annulus; inner frame holds trileaflet bovine pericardial valve. APOLLO trial (NCT03242642).",tc_style)], [P("EVOQUE",tc_style), P("Edwards",tc_style), P("Transfemoral Transseptal",tc_style), P("Trileaflet bovine pericardial; nitinol frame; intra-annular sealing skirt; ventricular anchors capture leaflets + chordae. MISCEND trial (NCT02718001). Also used for tricuspid replacement.",tc_style)], [P("Tiara",tc_style), P("Neovasc",tc_style), P("Transapical",tc_style), P("Early feasibility",tc_style)], [P("AltaValve",tc_style), P("4C Medical",tc_style), P("Transapical",tc_style), P("Early feasibility",tc_style)], [P("Cardiovalve",tc_style), P("Cardiovalve",tc_style), P("Transseptal",tc_style), P("Early feasibility",tc_style)], [P("SAPIEN M3",tc_style), P("Edwards",tc_style), P("Transseptal",tc_style), P("Early feasibility",tc_style)], [P("HighLife",tc_style), P("Highlife SAS",tc_style), P("Combined",tc_style), P("Early feasibility",tc_style)], ] story.append(tbl(nd, cw=[2.8*cm,2.8*cm,3.5*cm,9*cm])) story.append(S(0.2)) story.append(P("EXAM TIP: Tendyne = Abbott, transapical, porcine valve, epicardial TETHER. Intrepid = Medtronic, outer-inner double frame. EVOQUE = Edwards, used for BOTH mitral AND tricuspid.", exam_style)) # ==== SECTION 4 ==== story.append(P("4. TRICUSPID VALVE INTERVENTIONS - OVERVIEW", h1_style)) story.append(P("4A. Etiology of TR", h2_style)) etd = [ [P("Type",th_style), P("Etiology",th_style), P("Mechanism",th_style)], [P("Secondary (most common)",tc_style), P("Left-sided heart disease, pulmonary HTN",tc_style), P("RV overload → annular dilation → leaflet tethering → malcoaptation",tc_style)], [P("Atrial Functional TR (Type I)",tc_style), P("Atrial fibrillation",tc_style), P("LA dilation → annular dilation with NORMAL LV",tc_style)], [P("Lead-induced",tc_style), P("Pacemaker / ICD leads",tc_style), P("Traumatic leaflet damage",tc_style)], [P("Primary",tc_style), P("IE, congenital, carcinoid",tc_style), P("Direct valve pathology",tc_style)], [P("Tricuspid stenosis",tc_style), P("Rheumatic fever (most common)",tc_style), P("Leaflet thickening / fusion",tc_style)], ] story.append(tbl(etd, cw=[4*cm,5*cm,9*cm])) story.append(S(0.2)) story.append(P("4B. Preprocedural Evaluation", h2_style)) for t in [ "Echocardiography (TEE/TTE): Primary modality - device sizing, leaflet anatomy, EROA, jet", "CT scan: Detailed tricuspid apparatus morphology, landing zone, anchoring sites, RCA, papillary muscles, IVC size", "Cardiac MRI: RV volumes, tricuspid regurgitant volume and EROA quantification", "Malcoaptation at anteroposterior and posteroseptal commissures (septal leaflet annulus relatively constant)", ]: story.append(bul(t)) story.append(P("4C. Classification of Transcatheter TV Therapies", h2_style)) for t in [ "Leaflet coaptation devices: MitraClip/TriClip, PASCAL, FORMA, Mistral, CroiValve", "Annuloplasty devices: Cardioband, TriAlign, TriCinch, TRI-RING", "Orthotopic replacement: EVOQUE, Intrepid, SAPIEN (ViV/ViR), Trisol, GATE, Lux-Valve", "Heterotopic (caval) replacement: SAPIEN XT/3 in IVC/SVC, TricValve, Tricento", ]: story.append(bul(t)) # ==== SECTION 5 ==== story.append(P("5. LEAFLET COAPTATION DEVICES (Tricuspid)", h1_style)) story.append(P("5A. MitraClip / TriClip", h2_style)) for t in [ "Off-label MitraClip use on TV: extensive early experience", "Challenges vs mitral: larger annulus, thinner and more fragile leaflets", "Clip configurations: approximate A + S leaflets → bicuspid valve; OR connect all 3 → clover/trifoliate", "TriClip (Abbott): dedicated TV version of MitraClip", "TRILUMINATE trial (NCT03227757): low 1-yr mortality in high surgical risk; informed pivotal trial", ]: story.append(bul(t)) story.append(P("5B. PASCAL (Edwards) for Tricuspid", h3_style)) for t in [ "First used for TV repair 2018 by Fam et al.", "Favorable safety profile at 30 days; reduced TR and improved clinical status", "CLASP TR Early Feasibility Study (NCT03745313)", ]: story.append(bul(t)) story.append(P("5C. FORMA (Edwards) - DISCONTINUED", h3_style)) for t in [ "Foam-filled polymer balloon spacer + rail anchored in RV with 6-pronged nitinol anchor", "Mechanism: leaflets coaptate against the spacer to reduce regurgitant orifice area", "50% EROA reduction at 30 days; NO sustained improvement to 1 year; 7/25 still had severe TR", "Device discontinued; trials NCT02471807 and SPACER (NCT02787408) halted", ]: story.append(bul(t)) story.append(P("5D. Mistral (Mitralix)", h3_style)) for t in [ "Spiral-shaped device: rotated to grasp chordae tendineae and pull diverged leaflets together", "7 first-in-human cases; TR reduction and improved RV function at 30 days", "Trials: MATTERS (NCT04071652) and MATTERS II (NCT04073979)", ]: story.append(bul(t)) # ==== SECTION 6 ==== story.append(P("6. ANNULOPLASTY DEVICES (Tricuspid)", h1_style)) story.append(P("6A. TriAlign (Mitralign) - Kay Procedure Analogue", h2_style)) for t in [ "Transcatheter suture annuloplasty mimicking the Kay bicuspidization", "Two pledgets at anteroposterior and septoposterior commissures → sutured together", "SCOUT trial: 80% technical success; NYHA improvement; pledget dehiscence reported", "SCOUT II trial ongoing (NCT03225612)", ]: story.append(bul(t)) story.append(P("6B. TriCinch (4Tech Cardio)", h2_style)) for t in [ "Coil anchored to TV annulus + Dacron band to self-expanding nitinol stent in IVC", "Tethering force applied to downsize TV annulus", "PREVENT trial: 25% anchor detachment → design changed from screw to nitinol-coil anchor", "Further trials terminated by sponsor (NCT03632967, NCT03294200)", ]: story.append(bul(t)) story.append(P("6C. Cardioband Tricuspid (Edwards)", h2_style)) for t in [ "Dacron sleeve with contraction wire/screws cinched into TV annulus", "CE approval April 2018 after TRI-REPAIR trial (NCT02981953)", "Ongoing: TriBAND (Europe) and EFS NCT03382457 (USA)", ]: story.append(bul(t)) story.append(P("6D. TRI-RING (Cardiac Implants)", h2_style)) for t in [ "Two-stage: ring anchored → 90 days tissue healing → cinched down to reduce annular diameter", "Human trial ongoing (NCT03700918)", ]: story.append(bul(t)) # ==== SECTION 7 ==== story.append(P("7. ORTHOTOPIC TRICUSPID VALVE REPLACEMENT", h1_style)) ovd = [ [P("Device",th_style), P("Company",th_style), P("Key Features",th_style), P("Trial",th_style)], [P("EVOQUE",tc_style), P("Edwards",tc_style), P("Trileaflet bovine pericardial; nitinol frame; intra-annular sealing skirt; ventricular anchors capture leaflets + chordae; transfemoral",tc_style), P("TRISCEND II (pivotal)",tc_style)], [P("Intrepid TTVR",tc_style), P("Medtronic",tc_style), P("Self-expanding nitinol; outer+inner frame; bovine pericardial; early feasibility for both MV and TV",tc_style), P("NCT04433065",tc_style)], [P("SAPIEN ViV/ViR",tc_style), P("Edwards",tc_style), P("Balloon-expandable; degenerated bioprosthesis; SAPIEN XT → SAPIEN 3; first use 2011 (Van Garsse)",tc_style), P("Multiple registries; international multicenter",tc_style)], [P("Trisol",tc_style), P("Trisol Medical",tc_style), P("Single dome-shaped bovine pericardial leaflet on nitinol stent; functions as two leaflets; animal model proven",tc_style), P("NCT04905017",tc_style)], [P("GATE",tc_style), P("NaviGate",tc_style), P("Orthotopic; early animal testing",tc_style), P("Preclinical",tc_style)], [P("Lux-Valve",tc_style), P("Jenscare",tc_style), P("Orthotopic; early animal testing (China)",tc_style), P("Preclinical",tc_style)], ] story.append(tbl(ovd, cw=[3*cm,3*cm,8*cm,4*cm])) story.append(S(0.2)) story.append(P("EXAM TIP: EVOQUE = Edwards = both mitral AND tricuspid. TRISCEND II = pivotal trial for EVOQUE tricuspid. Trisol = single dome-shaped leaflet functioning as two.", exam_style)) # ==== SECTION 8 ==== story.append(P("8. HETEROTOPIC (CAVAL) TRICUSPID VALVE REPLACEMENT", h1_style)) for t in [ "Concept: place valve in IVC (and/or SVC) to reduce systemic venous reflux from TR = Caval Valve Implantation (CAVI)", "Goal: reduce hepatic and renal vein peak systolic pressures", "SAPIEN XT (TRICAVAL trial): Terminated - valve dislocation and stent migration complications", "HOVER trial (SAPIEN valves in IVC): NCT02339974 - ongoing; benefits not yet proven", "TricValve (P&F, Vienna): TWO valves - one in SVC + one in IVC; bovine pericardial + PTFE skirt", "TRICUS STUDY: NCT03723239 and NCT04141137 - TricValve safety/efficacy", "Multicenter study 25 patients: 8% 30-day mortality; technically feasible", "Tricento (New Valve Technology): IVC-anchor device; implemented in humans; no formal clinical trials yet", ]: story.append(bul(t)) story.append(P("EXAM TIP: TricValve = 2 valves (SVC + IVC). Tricento = anchors in IVC only. CAVI = heterotopic approach. TRICAVAL = terminated due to dislocation.", exam_style)) # ==== SECTION 9 ==== story.append(P("9. HIGH-YIELD COMPARISON TABLES", h1_style)) story.append(P("Mitral TEER vs Tricuspid TEER", h2_style)) ctd = [ [P("Feature",th_style), P("Mitral TEER",th_style), P("Tricuspid TEER",th_style)], [P("Annulus size",tc_style), P("Smaller",tc_style), P("Larger",tc_style)], [P("Leaflet characteristics",tc_style), P("Thicker, robust",tc_style), P("Thinner, fragile",tc_style)], [P("Primary device",tc_style), P("MitraClip (Abbott)",tc_style), P("TriClip (Abbott)",tc_style)], [P("Clip configuration",tc_style), P("Single/double MitraClip",tc_style), P("Bicuspid (A+S) or Clover (all 3)",tc_style)], [P("Evidence base",tc_style), P("Strong (EVEREST II, COAPT, MITRA-FR)",tc_style), P("Emerging (TRILUMINATE)",tc_style)], [P("FDA approval",tc_style), P("Yes (primary 2014; secondary 2020)",tc_style), P("No dedicated approval as of 2021",tc_style)], ] story.append(tbl(ctd, cw=[4.5*cm,6.25*cm,7.25*cm])) story.append(S(0.2)) story.append(P("Transcatheter TR Approach Summary", h2_style)) trtd = [ [P("Approach",th_style), P("Devices",th_style), P("Mechanism",th_style)], [P("Leaflet coaptation",tc_style), P("MitraClip/TriClip, PASCAL, FORMA (discontinued), Mistral",tc_style), P("Approximate valve leaflets / spacer to reduce regurgitation",tc_style)], [P("Annuloplasty",tc_style), P("Cardioband, TriAlign, TriCinch, TRI-RING",tc_style), P("Reduce annular diameter to restore leaflet coaptation",tc_style)], [P("Orthotopic replacement",tc_style), P("EVOQUE, Intrepid, SAPIEN ViV/ViR, Trisol",tc_style), P("Replace native valve in anatomic (tricuspid annular) position",tc_style)], [P("Heterotopic (caval)",tc_style), P("SAPIEN XT, TricValve, Tricento",tc_style), P("Valves in SVC/IVC to reduce caval venous reflux from TR",tc_style)], ] story.append(tbl(trtd, cw=[4*cm,6.5*cm,7.5*cm])) story.append(S(0.3)) # ==== SECTION 10 - PROBABLE EXAM QUESTIONS ==== story.append(P("10. PROBABLE EXAM QUESTIONS", h1_style)) pqd = [ [P("#",th_style), P("Topic",th_style), P("High-Yield Answer Point",th_style)], [P("1",tc_style), P("Alfieri technique",tc_style), P("Single stitch opposing free edges of A and P MV leaflets → double-orifice valve. Described early 1990s.",tc_style)], [P("2",tc_style), P("MitraClip access route",tc_style), P("Transvenous TRANSSEPTAL under GA with TEE guidance",tc_style)], [P("3",tc_style), P("EVEREST II primary endpoint",tc_style), P("Composite: freedom from death + MV surgery + >=3+ MR. Clip 55% vs surgery 73% (P=.007). Surgery SUPERIOR for primary endpoint but lower 30-day AE with clip.",tc_style)], [P("4",tc_style), P("COAPT vs MITRA-FR",tc_style), P("COAPT: disproportionate MR → BENEFIT. MITRA-FR: proportionate MR → NO benefit. Key: EROA relative to LVEDV.",tc_style)], [P("5",tc_style), P("COAPT FDA-approved criteria",tc_style), P("EF 20-50%; mod-severe or worse MR on GDMT; LVESD <7.0 cm; PA systolic <70 mmHg",tc_style)], [P("6",tc_style), P("Tendyne device",tc_style), P("Abbott; transapical; self-expanding nitinol; trileaflet porcine valve; epicardial tether. CE mark Jan 2020. SUMMIT trial.",tc_style)], [P("7",tc_style), P("TMVR ViV most common complication",tc_style), P("Bleeding (13%), AF (5%), MV reintervention (2%), stroke (2%). 30-day mortality 5%; 1-yr mortality 23%.",tc_style)], [P("8",tc_style), P("MAC and TMVR complications",tc_style), P("LVOTO and valve embolization. Managed by hybrid approach: anterior leaflet resection + direct implantation.",tc_style)], [P("9",tc_style), P("TV anatomy landmarks",tc_style), P("3 leaflets: Anterior (A), Posterior (P), Septal (S). AV node = blue spot near coronary sinus / tendon of Todaro.",tc_style)], [P("10",tc_style), P("Most common cause of TR",tc_style), P("Secondary (functional); left-sided disease → pulmonary HTN → RV overload → annular dilation",tc_style)], [P("11",tc_style), P("Most common cause of tricuspid stenosis",tc_style), P("Rheumatic fever",tc_style)], [P("12",tc_style), P("TriAlign / Kay procedure",tc_style), P("Kay bicuspidization: TriAlign mimics Kay by plicating posterior leaflet with 2 pledgets at AP and SP commissures.",tc_style)], [P("13",tc_style), P("FORMA device - what happened?",tc_style), P("Discontinued: 50% EROA reduction at 30 days BUT no sustained improvement at 1 year. 7/25 patients still had severe TR.",tc_style)], [P("14",tc_style), P("TricValve device",tc_style), P("TWO valves: one in SVC + one in IVC (heterotopic). TRICUS STUDY ongoing.",tc_style)], [P("15",tc_style), P("PASCAL vs MitraClip - differences",tc_style), P("PASCAL: central spacer + independent leaflet grasping + broader paddles + nitinol. CLASP IID/IIF = first head-to-head trial.",tc_style)], [P("16",tc_style), P("Atrial functional MR",tc_style), P("AF → dilated LA → annular dilation with NORMAL LV size and function. Distinct pathophysiology.",tc_style)], [P("17",tc_style), P("TriCinch PREVENT trial problem",tc_style), P("25% anchor detachment → device modified from screw tip to nitinol-coil anchor.",tc_style)], [P("18",tc_style), P("Cardioband TV regulatory status",tc_style), P("CE approval April 2018 after TRI-REPAIR trial. US: EFS NCT03382457.",tc_style)], [P("19",tc_style), P("Imaging for TV preprocedural planning",tc_style), P("Echo (primary), CT (landing zone/anatomy/RCA), CMR (RV volumes + TR quantification)",tc_style)], [P("20",tc_style), P("1-yr mortality after TEER",tc_style), P("~25% at 1 year from TVT registry; similar for primary and secondary MR",tc_style)], ] story.append(tbl(pqd, cw=[0.7*cm,4.3*cm,13*cm])) story.append(S(0.3)) # ==== SECTION 11 - MEMORY AIDS ==== story.append(P("11. MEMORY AIDS & MNEMONICS", h1_style)) story.append(P("COAPT vs MITRA-FR:", h3_style)) story.append(P("COAPT = 'Can Optimize And Provide Therapy' for disproportionate MR (EROA >> LVEDV).\nMITRA-FR = 'More proportionate' = No benefit beyond GDMT.", memory_style)) story.append(P("Alfieri → MitraClip lineage:", h3_style)) story.append(P("Alfieri (1990s) → double-orifice via single stitch → MitraClip reproduces this mechanically → transvenous, transseptal", memory_style)) story.append(P("Tendyne Device:", h3_style)) story.append(P("TENDYNE: Tether (epicardial) + Abbott + Nitinol frame + porcine valve + Deployed transapically + Year CE = 2020", memory_style)) story.append(P("TV Annuloplasty Devices - TTCT:", h3_style)) story.append(P("TriAlign (Kay-like bicuspidization) | TriCinch (IVC tethering stent) | Cardioband Tricuspid (Dacron/screws) | TRI-RING (2-stage cinch)", memory_style)) story.append(P("Heterotopic = CAVI (Caval Valve Implantation):", h3_style)) story.append(P("TricValve = 2 valves (SVC + IVC) | Tricento = IVC anchor | SAPIEN XT = TRICAVAL (terminated) / HOVER (ongoing)", memory_style)) story.append(P("FORMA failed: 'FORMA could not FORMA sustained result'", h3_style)) story.append(P("Spacer device (balloon in RV) - 50% EROA reduction at 30 days only. Device DISCONTINUED.", memory_style)) story.append(S(0.5)) story.append(HR()) story.append(P("Prepared for INI SS CET CVTS | Chapter 60: Transcatheter Treatment of Mitral and Tricuspid Valve Disease", subtitle_style)) story.append(P("Source: DiMaio JM, Shih E, Squiers JJ, Mack MJ. Section 2 - Adult Cardiac Surgery. Pages 1121-1136.", subtitle_style)) doc.build(story) print("SUCCESS:", OUTPUT_PATH) PYEOF python3 /home/daytona/workspace/ch60_output/generate_teaching_notes.py

Teaching notes PDF done. Now generating the 20 MCQs PDF with images.

Running Command

# Extract images directly from the PDF using pdfplumber (save crops as PIL images) python3 << 'EOF' import pdfplumber from PIL import Image as PILImage import io, os pdf_path = '/home/daytona/workspace/attachments/43826880-c2b8-4a74-848d-7076ac1a6dd0/Chapter_60_PDF_pages_168-183.pdf' out_dir = '/home/daytona/workspace/ch60_output/mcq_images' os.makedirs(out_dir, exist_ok=True) # Pages with relevant figures: 2 (fig60.1), 3 (fig60.2), 5 (fig60.4), 6 (fig60.6), 8 (fig60.7), 10 (fig60.8/60.9) pages_to_crop = { 2: [('fig60_1_mv_anatomy', 47, 113, 295, 295)], # x0,y0,x1,y1 in points approx 10: [('fig60_8_tv_anatomy', 143, 536, 456, 730), ('fig60_9_tr_echo', 83, 189, 516, 495)], } with pdfplumber.open(pdf_path) as pdf: for page_num, crops in pages_to_crop.items(): page = pdf.pages[page_num - 1] page_img = page.to_image(resolution=200) pil_img = page_img.original # PIL Image w, h = pil_img.size pw = page.width # points ph = page.height for name, x0, y0, x1, y1 in crops: # convert points to pixels px0 = int(x0 / pw * w) py0 = int(y0 / ph * h) px1 = int(x1 / pw * w) py1 = int(y1 / ph * h) cropped = pil_img.crop((px0, py0, px1, py1)) out_path = os.path.join(out_dir, f'{name}.png') cropped.save(out_path) print(f"Saved {out_path} ({cropped.size})") print("Done extracting images from PDF") EOF

Running Command

# Extract more figures - pages 3 (fig60.2 - MitraClip echo), 6 (repair devices), 8 (fig60.7 - TMVR devices), 11 (fig60.10 overview) python3 << 'EOF' import pdfplumber from PIL import Image as PILImage import io, os pdf_path = '/home/daytona/workspace/attachments/43826880-c2b8-4a74-848d-7076ac1a6dd0/Chapter_60_PDF_pages_168-183.pdf' out_dir = '/home/daytona/workspace/ch60_output/mcq_images' os.makedirs(out_dir, exist_ok=True) pages_to_crop = { 3: [('fig60_2_mitraclip_echo', 60, 390, 565, 740)], # fig 60.2 - MitraClip echo images A-D 6: [('fig60_6_repair_devices', 40, 60, 545, 240)], # fig 60.6 - TMVr repair devices 8: [('fig60_7_tmvr_devices', 75, 100, 530, 615)], # fig 60.7 - TMVR replacement devices 11: [('fig60_10_tricuspid_overview', 270, 430, 545, 720)], # fig 60.10 - overview diagram } with pdfplumber.open(pdf_path) as pdf: for page_num, crops in pages_to_crop.items(): page = pdf.pages[page_num - 1] page_img = page.to_image(resolution=200) pil_img = page_img.original w, h = pil_img.size pw = page.width ph = page.height for name, x0, y0, x1, y1 in crops: px0 = int(x0 / pw * w) py0 = int(y0 / ph * h) px1 = int(x1 / pw * w) py1 = int(y1 / ph * h) cropped = pil_img.crop((px0, py0, px1, py1)) out_path = os.path.join(out_dir, f'{name}.png') cropped.save(out_path) print(f"Saved {out_path} ({cropped.size})") print("Done") EOF ls -la /home/daytona/workspace/ch60_output/mcq_images/

All images extracted. Now generating the complete 20-MCQ PDF:

Running Command

cat > /home/daytona/workspace/ch60_output/generate_mcqs.py << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import mm, cm from reportlab.lib import colors from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, PageBreak, Image, KeepTogether) from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY import os OUTPUT_PATH = '/home/daytona/workspace/ch60_output/Ch60_MCQs_INI_SS_CET.pdf' IMG_DIR = '/home/daytona/workspace/ch60_output/mcq_images' doc = SimpleDocTemplate(OUTPUT_PATH, pagesize=A4, rightMargin=2*cm, leftMargin=2*cm, topMargin=2*cm, bottomMargin=2*cm) styles = getSampleStyleSheet() W = doc.width title_style = ParagraphStyle('CT', parent=styles['Heading1'], fontSize=18, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a3a5c'), spaceAfter=4, spaceBefore=4, alignment=TA_CENTER) subtitle_style = ParagraphStyle('ST', parent=styles['Normal'], fontSize=10, fontName='Helvetica', textColor=colors.HexColor('#555555'), spaceAfter=6, alignment=TA_CENTER) q_num_style = ParagraphStyle('QN', parent=styles['Normal'], fontSize=12, fontName='Helvetica-Bold', textColor=colors.white, spaceBefore=4, spaceAfter=2, backColor=colors.HexColor('#1a3a5c'), leftIndent=0, rightIndent=0, borderPad=5) para_style = ParagraphStyle('Para', parent=styles['Normal'], fontSize=10, fontName='Helvetica', textColor=colors.HexColor('#333333'), backColor=colors.HexColor('#f0f4fa'), spaceAfter=6, spaceBefore=4, leading=14, leftIndent=8, rightIndent=8, borderPad=5, alignment=TA_JUSTIFY) q_style = ParagraphStyle('Q', parent=styles['Normal'], fontSize=11, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a1a1a'), spaceAfter=4, spaceBefore=4, leading=15) opt_style = ParagraphStyle('Opt', parent=styles['Normal'], fontSize=10, fontName='Helvetica', textColor=colors.HexColor('#222222'), spaceAfter=2, spaceBefore=1, leading=13, leftIndent=12) ans_style = ParagraphStyle('Ans', parent=styles['Normal'], fontSize=10, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a5c1a'), backColor=colors.HexColor('#efffef'), spaceAfter=3, spaceBefore=4, leading=13, leftIndent=6, rightIndent=6, borderPad=4) exp_style = ParagraphStyle('Exp', parent=styles['Normal'], fontSize=9, fontName='Helvetica', textColor=colors.HexColor('#444444'), backColor=colors.HexColor('#f7f7f7'), spaceAfter=6, spaceBefore=2, leading=13, leftIndent=6, rightIndent=6, borderPad=4) img_cap_style = ParagraphStyle('ImgCap', parent=styles['Normal'], fontSize=8, fontName='Helvetica-Oblique', textColor=colors.HexColor('#666666'), spaceAfter=4, spaceBefore=2, alignment=TA_CENTER) HR = lambda: HRFlowable(width="100%", thickness=0.5, color=colors.HexColor('#bbbbbb'), spaceAfter=4) S = lambda h=0.25: Spacer(1, h*cm) def P(text, style): return Paragraph(text, style) def img(fname, width_cm=12, caption=None): path = os.path.join(IMG_DIR, fname) if not os.path.exists(path): return [P(f'[Image: {fname} not found]', exp_style)] i = Image(path) i.drawWidth = width_cm * cm ratio = i._imageWidth / i._imageHeight if hasattr(i, '_imageWidth') else 1.5 try: from PIL import Image as PILImage pil = PILImage.open(path) ratio = pil.size[0] / pil.size[1] except: pass i.drawHeight = i.drawWidth / ratio elems = [i] if caption: elems.append(P(caption, img_cap_style)) return elems def q_block(num, stem, options, answer, explanation, para=None, image_fname=None, img_width=13, img_caption=None, img_position='after_q'): """Build a complete question block.""" elems = [] elems.append(S(0.2)) header_elems = [P(f'Question {num}', q_num_style)] if para: header_elems.append(P(para, para_style)) # Optionally show image before or after question if image_fname and img_position == 'before_q': header_elems.extend(img(image_fname, img_width, img_caption)) header_elems.append(P(stem, q_style)) if image_fname and img_position == 'after_q': header_elems.extend(img(image_fname, img_width, img_caption)) for opt in options: header_elems.append(P(opt, opt_style)) elems.append(KeepTogether(header_elems)) elems.append(P(f'Correct Answer: {answer}', ans_style)) elems.append(P(f'Explanation: {explanation}', exp_style)) elems.append(HR()) return elems story = [] # ==== COVER ==== story += [S(0.5), P("INI SS CET - CVTS | Chapter 60", subtitle_style), P("Transcatheter Treatment of Mitral and Tricuspid Valve Disease", title_style), P("20 Single Best Answer MCQs | INI SS CET Format", subtitle_style), HRFlowable(width="100%", thickness=2, color=colors.HexColor('#1a3a5c'), spaceAfter=10), S(0.2)] info_data = [ ['Examination', 'INI SS CET - CVTS (CardioVascular and Thoracic Surgery)'], ['Question Type', 'Single Best Answer (SBA) Multiple Choice Questions'], ['Chapter', 'Chapter 60: Transcatheter Treatment of Mitral and Tricuspid Valve Disease'], ['Source', 'DiMaio JM, Shih E, Squiers JJ, Mack MJ. Adult Cardiac Surgery Textbook, pp 1121-1136'], ['Total Questions', '20 (including 5 image-based questions)'], ['Format', 'Paragraph / clinical vignette + image questions in INI SS CET style'], ] info_tbl = Table(info_data, colWidths=[5*cm, 13*cm]) info_tbl.setStyle(TableStyle([ ('BACKGROUND', (0,0), (0,-1), colors.HexColor('#eef4fb')), ('FONTNAME', (0,0), (0,-1), 'Helvetica-Bold'), ('FONTNAME', (1,0), (1,-1), 'Helvetica'), ('FONTSIZE', (0,0), (-1,-1), 9), ('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#cccccc')), ('TOPPADDING', (0,0), (-1,-1), 5), ('BOTTOMPADDING', (0,0), (-1,-1), 5), ('LEFTPADDING', (0,0), (-1,-1), 6), ('RIGHTPADDING', (0,0), (-1,-1), 6), ('VALIGN', (0,0), (-1,-1), 'MIDDLE'), ])) story.append(info_tbl) story.append(S(0.5)) story.append(PageBreak()) # ================================================================== # QUESTIONS # ================================================================== # Q1 - BASIC ANATOMY / IMAGE story += q_block( num=1, image_fname='fig60_1_mv_anatomy.png', img_width=10, img_caption='Fig 60.1. Mitral valve anatomy. (Source: DiMaio et al., Chapter 60, Adult Cardiac Surgery Textbook, pp 1121-1136; adapted from Ye Z et al., J Cardiothorac Vasc Anesth. 2022;36[2]:429-436)', img_position='before_q', stem='The image above depicts the normal mitral valve anatomy. Asterisks in the original figure represent normal indentations and scallops. Which of the following correctly describes the primary structural components of the mitral valve apparatus that must function in an integrated manner to prevent regurgitation?', options=[ 'A. Leaflets, chordae tendineae, papillary muscles, and annulus', 'B. Leaflets, annulus, myocardium, and pericardium', 'C. Chordae tendineae, aortic valve, papillary muscles, and annulus', 'D. Annulus, sinus of Valsalva, papillary muscles, and leaflets', ], answer='A. Leaflets, chordae tendineae, papillary muscles, and annulus', explanation='The mitral valve is a complex structure requiring integrated function of its four components: leaflets, chordae tendineae, papillary muscles, and annulus. Dysfunction of any one component can result in regurgitation. The aortic valve and sinus of Valsalva are not part of the mitral valve apparatus.', ) # Q2 - CLINICAL VIGNETTE - PRIMARY vs SECONDARY MR story += q_block( num=2, para='A 72-year-old man with a prior history of ischaemic cardiomyopathy presents with worsening dyspnoea (NYHA III). Echocardiography shows a dilated left ventricle (LVESD 55 mm), LVEF 30%, and severe mitral regurgitation due to posterior papillary muscle displacement with no structural leaflet abnormality.', stem='What is the most accurate classification of this patient\'s mitral regurgitation, and what does current evidence suggest regarding surgical treatment?', options=[ 'A. Primary MR; surgical repair is superior to replacement', 'B. Secondary (functional) MR; replacement provides more durable correction than repair', 'C. Secondary (functional) MR; repair is superior to replacement regardless of LV function', 'D. Primary MR; transcatheter edge-to-edge repair is the first-line treatment', ], answer='B. Secondary (functional) MR; replacement provides more durable correction than repair', explanation='This patient has secondary (functional) MR resulting from LV dilation/dysfunction distorting the mitral valve annulus - there is no primary structural leaflet defect. Current evidence suggests that for secondary MR, mitral valve replacement provides more durable correction of MR than repair. In primary MR (structural leaflet disease), surgical repair is superior to replacement.', ) # Q3 - ALFIERI TECHNIQUE story += q_block( num=3, stem='The MitraClip device is designed to mimic which surgical technique for mitral valve repair?', options=[ 'A. Ring annuloplasty (Carpentier technique)', 'B. Resection of the posterior leaflet (Carpentier resection)', 'C. Edge-to-edge repair (Alfieri technique)', 'D. Artificial chordal implantation (NeoChord technique)', ], answer='C. Edge-to-edge repair (Alfieri technique)', explanation='The MitraClip device reproduces the "edge-to-edge" technique described by Alfieri in the early 1990s. Alfieri\'s technique uses a single stitch to oppose the free edges of the anterior and posterior mitral valve leaflets, creating a double-orifice valve apparatus. The MitraClip mechanically replicates this by grasping and opposing these leaflets via a transvenous transseptal approach.', ) # Q4 - MITRACLIP ACCESS story += q_block( num=4, stem='A 78-year-old woman with severe primary MR is deemed prohibitive surgical risk. The heart team decides to proceed with MitraClip (TEER). Which of the following best describes the access route and guidance used for this procedure?', options=[ 'A. Transarterial retrograde approach; fluoroscopy alone', 'B. Transapical left ventricular approach; intracardiac echocardiography', 'C. Transvenous transseptal approach; transesophageal echocardiography under general anaesthesia', 'D. Transvenous transseptal approach; transthoracic echocardiography under local anaesthesia', ], answer='C. Transvenous transseptal approach; transesophageal echocardiography under general anaesthesia', explanation='The MitraClip procedure is performed via a transvenous, transseptal approach (accessing the left atrium by puncturing the interatrial septum). It is performed under general anaesthesia with transesophageal echocardiography (TEE) guidance. More than one clip may be placed (in approximately 50% of cases).', ) # Q5 - EVEREST II story += q_block( num=5, para='The EVEREST II trial randomized 258 patients (178 MitraClip vs 80 surgery) with moderately severe or severe MR to transcatheter edge-to-edge repair or surgical mitral valve repair/replacement. The majority (73%) had degenerative MR. The primary efficacy endpoint was composite freedom from death, surgery for mitral valve dysfunction, and >=3+ MR.', stem='What was the 30-day adverse event rate in the MitraClip group versus the surgical group in EVEREST II, and what was the primary reason for the higher adverse event rate in the surgical group?', options=[ 'A. MitraClip 30% vs Surgery 15%; higher rates of stroke in surgical group', 'B. MitraClip 15% vs Surgery 48%; higher rates of postoperative transfusion in surgical group', 'C. MitraClip 48% vs Surgery 15%; higher rates of reintervention in MitraClip group', 'D. MitraClip 2% vs Surgery 10%; higher rates of pacemaker implantation in surgical group', ], answer='B. MitraClip 15% vs Surgery 48%; higher rates of postoperative transfusion in surgical group', explanation='In EVEREST II, 30-day adverse events were substantially lower in the MitraClip group (15% vs 48%). The primary reason was significantly higher rates of postoperative transfusion in the surgical group. However, the primary efficacy endpoint was met less frequently in the MitraClip cohort (55%) versus surgery (73%, P=0.007), with higher rates of reintervention in the MitraClip group within the first year.', ) # Q6 - COAPT vs MITRA-FR IMAGE story += q_block( num=6, image_fname='fig60_2_mitraclip_echo.png', img_width=13, img_caption='Fig 60.2. Echocardiographic imaging of residual mitral regurgitation after MitraClip showing bicommissural view, valve anatomy, and multiplanar reconstruction. Solid arrow = residual MR; dashed arrow = MitraClip. (Source: DiMaio et al., Chapter 60, pp 1121-1136; adapted from Ramchand J, Miyasaka R. Cardiol Clin. 2021;39[2]:267-280, with permission from Elsevier)', img_position='before_q', stem='The COAPT trial demonstrated a significant survival benefit with MitraClip at 2 years in patients with secondary MR, whereas the MITRA-FR trial showed no benefit. The figure above shows echocardiographic assessment after MitraClip placement. Which patient characteristic best explains the difference in outcomes between COAPT and MITRA-FR?', options=[ 'A. COAPT enrolled patients with primary MR; MITRA-FR enrolled secondary MR', 'B. COAPT patients had disproportionately severe MR relative to LVEDV; MITRA-FR had proportionate MR', 'C. COAPT used a newer generation MitraClip; MITRA-FR used an older model', 'D. COAPT had a larger sample size and therefore greater statistical power', ], answer='B. COAPT patients had disproportionately severe MR relative to LVEDV; MITRA-FR had proportionate MR', explanation='The key reconciling hypothesis is that COAPT enrolled patients with DISPROPORTIONATELY severe MR (EROA high relative to LVEDV) who derive the most benefit from device-based therapy, whereas MITRA-FR enrolled patients with PROPORTIONATE MR (EROA commensurate with the dilated LV). Both trials enrolled secondary MR patients. COAPT showed 2-yr rehospitalization 35.8% vs 67.9% and mortality 29.1% vs 46.1% in favour of MitraClip.', ) # Q7 - COAPT INCLUSION CRITERIA story += q_block( num=7, para='Following FDA approval of MitraClip for secondary MR in 2020, a 68-year-old man with ischaemic cardiomyopathy and secondary MR is evaluated. He has: LVEF 35%, moderate-to-severe MR despite optimised GDMT, LVESD 6.5 cm, PA systolic pressure 65 mmHg.', stem='Based on the FDA-approved inclusion criteria derived from the COAPT trial, is this patient eligible for MitraClip for secondary MR?', options=[ 'A. No - LVEF is too low (<40%)', 'B. No - PA systolic pressure exceeds the threshold of 60 mmHg', 'C. Yes - all criteria are met (EF 20-50%, MR on GDMT, LVESD <7.0 cm, PA systolic <70 mmHg)', 'D. No - LVESD must be <5.5 cm for eligibility', ], answer='C. Yes - all criteria are met (EF 20-50%, MR on GDMT, LVESD <7.0 cm, PA systolic <70 mmHg)', explanation='FDA-approved COAPT-based inclusion criteria for MitraClip in secondary MR: (1) EF between 20% and 50% - this patient has 35% [PASS]; (2) Moderate-to-severe or worse MR despite optimised GDMT [PASS]; (3) LVESD < 7.0 cm - this patient has 6.5 cm [PASS]; (4) PA systolic < 70 mmHg - this patient has 65 mmHg [PASS]. All criteria are met.', ) # Q8 - PASCAL SYSTEM story += q_block( num=8, stem='The PASCAL transcatheter mitral valve repair system differs from MitraClip in several important ways. Which of the following is a unique feature of the PASCAL system?', options=[ 'A. It is delivered via a transapical approach', 'B. It contains a central spacer and allows independent leaflet grasping', 'C. It is the only system with FDA approval for both primary and secondary MR', 'D. It uses a balloon-expandable metal frame rather than nitinol', ], answer='B. It contains a central spacer and allows independent leaflet grasping', explanation='The PASCAL system (Edwards Lifesciences) differs from MitraClip by its nitinol structure with a CENTRAL SPACER (to reduce stress on leaflets), INDEPENDENT leaflet grasping capability, and broader paddles. It has CE mark approval in Europe. The CLASP IID and IIF Pivotal Clinical Trials (NCT03706822) represent the first head-to-head trial comparing PASCAL vs MitraClip.', ) # Q9 - REAL WORLD OUTCOMES story += q_block( num=9, para='Data from the STS-ACC TVT registry, which captured over 10,000 commercial TEER procedures performed in the United States in 2019, provides important real-world outcome benchmarks for transcatheter edge-to-edge repair.', stem='Which of the following best describes the real-world outcomes at 30 days and 1 year from the TVT registry for TEER?', options=[ 'A. In-hospital mortality ~5%; 30-day mortality ~10%; 1-year mortality ~15%', 'B. In-hospital mortality ~2%; 30-day mortality ~4.5%; 1-year mortality ~25%', 'C. In-hospital mortality ~1%; 30-day mortality ~2%; 1-year mortality ~10%', 'D. In-hospital mortality ~8%; 30-day mortality ~12%; 1-year mortality ~40%', ], answer='B. In-hospital mortality ~2%; 30-day mortality ~4.5%; 1-year mortality ~25%', explanation='TVT Registry real-world TEER outcomes: in-hospital mortality ~2%, stroke <1%, conversion to MV surgery <5/1000. 30-day mortality ~4.5%. MR reduced to less than moderate-severe in >90% by 30 days. However, MV gradient >5 mmHg present in ~25% post-TEER. 1-year mortality is ~25%, similar for primary and secondary MR - highlighting the importance of improved patient selection.', ) # Q10 - CARDIOBAND / NeoChord story += q_block( num=10, stem='Which transcatheter mitral valve repair device consists of a polyester sleeve with an embedded contraction wire implanted along the posterior mitral annulus on the beating heart, and has received European regulatory approval but not FDA approval?', options=[ 'A. NeoChord DS1000', 'B. MitraClip', 'C. Cardioband (Edwards Lifesciences)', 'D. PASCAL system', ], answer='C. Cardioband (Edwards Lifesciences)', explanation='The Cardioband system (Edwards Lifesciences) is a transcatheter direct annuloplasty device composed of a polyester sleeve with an embedded contraction wire. It is implanted on the beating heart along the posterior mitral annulus under fluoroscopic and echocardiographic guidance. It has European regulatory approval but not FDA approval. The NeoChord DS1000 is a chordal implantation device (transapical); MitraClip and PASCAL are edge-to-edge repair devices.', ) # Q11 - TMVR ViV story += q_block( num=11, para='A 76-year-old woman underwent surgical MVR with a bioprosthesis 12 years ago. She now presents with severe symptomatic mitral valve stenosis due to bioprosthetic valve degeneration. Her STS predicted risk of mortality for redo surgery is 12%.', stem='Which of the following best describes the regulatory status and outcomes of transcatheter mitral valve-in-valve (ViV) replacement for this indication?', options=[ 'A. FDA approved in 2014; 30-day mortality 1%; 1-year mortality 8%; MR reduced <=moderate in 85% of cases', 'B. FDA approved in 2017; 30-day mortality ~5%; 1-year mortality ~23%; MR reduced <=moderate in >99% of cases', 'C. Not FDA approved; only available as compassionate use; 30-day mortality ~15%', 'D. FDA approved in 2020; 30-day mortality ~2%; 1-year mortality ~10%; preferred approach remains transapical', ], answer='B. FDA approved in 2017; 30-day mortality ~5%; 1-year mortality ~23%; MR reduced <=moderate in >99% of cases', explanation='The FDA approved TMVR for degenerated mitral bioprostheses using balloon-expandable transcatheter valves in 2017. TVT Registry (2014-2020, >3000 procedures): 30-day mortality 5%, 1-year mortality 23%. Most common complications: bleeding (13%), AF (5%), MV reintervention (2%), stroke (2%). MR reduced to <=moderate in >99%. There is a clear trend toward transseptal (rather than transapical) approach in recent years.', ) # Q12 - TMVR DEVICES IMAGE story += q_block( num=12, image_fname='fig60_7_tmvr_devices.png', img_width=12, img_caption='Fig 60.7. Transcatheter mitral valve replacement devices. (A) Intrepid - Medtronic; (B) Tendyne - Abbott; (C) Tiara - Neovasc; (D) AltaValve - 4C Medical; (E) Cardiovalve; (F) Cephea Valve - Abbott; (G) EVOQUE - Edwards Lifesciences; (H) HighLife Valve; (I) SAPIEN M3 - Edwards Lifesciences. (Source: DiMaio et al., Chapter 60, pp 1121-1136; adapted from Hensey M et al. JACC Cardiovasc Interv. 2021;14[5]:489-500, with permission from Elsevier)', img_position='before_q', stem='Based on the image above showing transcatheter mitral valve replacement devices, which of the following correctly pairs the device with its manufacturer and key distinguishing feature?', options=[ 'A. Tendyne (Medtronic) - delivered transapically; trileaflet bovine pericardial valve; outer oversized frame anchors onto annulus', 'B. Intrepid (Abbott) - outer oversized frame anchors onto annulus; inner frame holds trileaflet bovine pericardial valve', 'C. EVOQUE (Edwards Lifesciences) - trileaflet bovine pericardial valve; ventricular anchors capture native leaflets and chordae; used for mitral AND tricuspid replacement', 'D. Tendyne (Abbott) - transapical delivery; porcine valve; epicardial tether anchored at apex', ], answer='C. EVOQUE (Edwards Lifesciences) - trileaflet bovine pericardial valve; ventricular anchors capture native leaflets and chordae; used for mitral AND tricuspid replacement', explanation='EVOQUE (Edwards Lifesciences) is a trileaflet bovine pericardial tissue valve in a nitinol frame with intra-annular sealing skirt and ventricular side anchors capturing mitral leaflets/chordae. Uniquely, EVOQUE has been developed for BOTH mitral (MISCEND trial) and tricuspid (TRISCEND II trial) replacement. Tendyne is Abbott (not Medtronic), delivered transapically with an epicardial polyethylene tether. Intrepid is Medtronic.', ) # Q13 - TENDYNE story += q_block( num=13, stem='The Tendyne transcatheter mitral valve system received European regulatory approval in January 2020. Which of the following best describes its design?', options=[ 'A. Balloon-expandable nitinol frame; bovine pericardial trileaflet valve; delivered via transseptal approach; sewn to annulus', 'B. Self-expanding nitinol frame; trileaflet porcine valve; delivered transapically; polyethylene tether secured epicardially at the apex', 'C. Self-expanding nitinol frame; bovine pericardial valve; delivered transapically; no tether required', 'D. Nitinol outer anchor frame + inner valve frame; bovine pericardial valve; delivered via transseptal approach', ], answer='B. Self-expanding nitinol frame; trileaflet porcine valve; delivered transapically; polyethylene tether secured epicardially at the apex', explanation='The Tendyne system (Abbott) consists of a self-expanding nitinol frame that positions a trileaflet PORCINE valve onto the native mitral annulus. Delivered via transapical approach. The implant is connected to a polyethylene TETHER secured epicardially at the apex (distinguishing feature). CE mark January 2020. Under investigation in SUMMIT trial (NCT03433274). Reverse LV remodeling observed as early as 1 month after implantation.', ) # Q14 - MAC TMVR story += q_block( num=14, stem='Which of the following are the two most clinically significant complications unique to transcatheter mitral valve replacement in patients with severe mitral annular calcification (MAC) compared to standard TMVR?', options=[ 'A. Coronary artery occlusion and pericardial effusion', 'B. Left ventricular outflow tract (LVOT) obstruction and valve embolization', 'C. Atrioventricular block and complete heart block', 'D. Pulmonary vein stenosis and stroke', ], answer='B. Left ventricular outflow tract (LVOT) obstruction and valve embolization', explanation='In severe MAC, the two main specific complications of transcatheter valve placement are: (1) LVOT obstruction - due to calcified annular tissue displacing the anterior mitral leaflet toward the LVOT, and (2) valve embolization - due to inadequate anchorage in the calcium. A hybrid surgical approach (resecting the mid-portion of the anterior leaflet + limited sutures + septal myomectomy) has been developed to mitigate these risks.', ) # Q15 - TV ANATOMY IMAGE story += q_block( num=15, image_fname='fig60_8_tv_anatomy.png', img_width=10, img_caption='Fig 60.8. Anatomy of the tricuspid valve via right atriotomy. A = anterior leaflet; P = posterior leaflet; S = septal leaflet; SVC = superior vena cava; TT = tendon of Todaro; CS = coronary sinus; IVC = inferior vena cava. Blue spot = location of atrioventricular node. (Source: DiMaio et al., Chapter 60, pp 1121-1136; adapted from Rodes-Cabau et al., with permission from Elsevier)', img_position='before_q', stem='Based on the anatomical image of the tricuspid valve shown above, which leaflet of the tricuspid valve remains relatively stable in size during progressive tricuspid annular dilation, and why is this clinically important?', options=[ 'A. Anterior leaflet; it is the largest and most mobile, so it compensates for annular dilation', 'B. Posterior leaflet; it is tethered by dense chordae preventing dilation', 'C. Septal leaflet; the annulus along the septal leaflet remains relatively constant, causing malcoaptation primarily at the anteroposterior and posteroseptal commissures', 'D. All three leaflets dilate equally; commissural malcoaptation is evenly distributed', ], answer='C. Septal leaflet; the annulus along the septal leaflet remains relatively constant, causing malcoaptation primarily at the anteroposterior and posteroseptal commissures', explanation='The tricuspid annulus preferentially dilates along the anterior and posterior leaflets. The annulus along the SEPTAL leaflet remains relatively constant. This results in malcoaptation primarily between the anteroposterior (AP) and posteroseptal (PS) commissures. This anatomy guides clip placement: clips approximate the anterior and septal leaflets to create a bicuspid valve, or all three leaflets to create a trifoliate ("clover") configuration.', ) # Q16 - TR ECHO IMAGE story += q_block( num=16, image_fname='fig60_9_tr_echo.png', img_width=13, img_caption='Fig 60.9. Echocardiography demonstrating tricuspid regurgitation. (A) Central jet in four-chamber view; (B) Hepatic vein systolic flow reversal; (C) Measurement of "neck" of TR at the level of the tricuspid valve. (Source: DiMaio et al., Chapter 60, pp 1121-1136; adapted from Rodes-Cabau J et al. Lancet. 2016;388[10058]:2431-2442, with permission from Elsevier)', img_position='before_q', stem='The echocardiographic findings shown in the image above are being evaluated prior to a transcatheter tricuspid valve intervention. In addition to echocardiography, which imaging modality provides the most detailed information about tricuspid valve apparatus morphology, landing zone anatomy, and surrounding structures such as the right coronary artery?', options=[ 'A. Chest X-ray', 'B. Cardiac MRI', 'C. CT scan / CT reconstruction', 'D. Nuclear stress test', ], answer='C. CT scan / CT reconstruction', explanation='While echocardiography is the primary imaging modality for preprocedural planning of transcatheter tricuspid interventions, CT reconstruction is increasingly utilized for more detailed assessment. CT provides detailed tricuspid apparatus and landing zone morphology, identification of anchoring sites, and broader evaluation of surrounding structures including the right coronary artery, papillary muscles, and inferior vena cava size. Cardiac MRI quantifies RV volumes and tricuspid regurgitant volume/EROA.', ) # Q17 - TRICLIP / TRILUMINATE story += q_block( num=17, stem='Which of the following most accurately describes the TriClip device and its evidence base for tricuspid regurgitation?', options=[ 'A. TriClip is a transcatheter annuloplasty device; pivotal trial showed 80% technical success with bicuspid valve creation', 'B. TriClip is a modified version of MitraClip designed for the tricuspid valve; TRILUMINATE trial demonstrated effective TR reduction at 1 year with low mortality in high surgical risk patients', 'C. TriClip is a heterotopic valve replacement device; TRISCEND II trial is ongoing for pivotal evidence', 'D. TriClip is the PASCAL transcatheter repair system redesigned for tricuspid use; first used by Fam et al. in 2018', ], answer='B. TriClip is a modified version of MitraClip designed for the tricuspid valve; TRILUMINATE trial demonstrated effective TR reduction at 1 year with low mortality in high surgical risk patients', explanation='TriClip (Abbott) is a modification of the MitraClip device specifically designed for the tricuspid valve. The TRILUMINATE study (NCT03227757) evaluated its short- and long-term safety and efficacy. Early feasibility trials showed effective TR reduction with sustained results to 1 year and low 1-year mortality in high surgical risk populations. The clips can create a bicuspid valve (A+S leaflets) or clover/trifoliate configuration (all 3 leaflets).', ) # Q18 - ANNULOPLASTY DEVICES story += q_block( num=18, stem='A patient with symptomatic chronic functional tricuspid regurgitation is enrolled in a clinical trial of a transcatheter suture annuloplasty device that mimics the surgical Kay procedure by plicating the posterior leaflet using two pledgets at the anteroposterior and septoposterior commissures, creating a bicuspid valve. The 30-day trial results showed 80% technical success but pledget dehiscence was reported. Which device is being described?', options=[ 'A. Cardioband tricuspid system', 'B. TriCinch coil system', 'C. TriAlign device (SCOUT trial)', 'D. TRI-RING neoannulus', ], answer='C. TriAlign device (SCOUT trial)', explanation='The TriAlign device (Mitralign Inc.) mimics the Kay surgical bicuspidization procedure. Two pledgets are positioned at the anteroposterior and septoposterior commissures and sutured together, plicating the posterior leaflet to create a bicuspid valve. The SCOUT trial (NCT02574650) showed 80% technical success and NYHA class improvement at 30 days. Pledget dehiscence was reported and is postulated to relate to pledget positioning. SCOUT II trial continues evaluation.', ) # Q19 - FORMA DEVICE story += q_block( num=19, stem='The FORMA system was a transcatheter device for tricuspid regurgitation that was subsequently discontinued. Which of the following best describes its mechanism and the reason for discontinuation?', options=[ 'A. Foam-filled polymer balloon spacer in RV; leaflets coaptate against it; discontinued due to 50% EROA reduction at 30 days that was not sustained at 1 year and 7/25 patients still had severe TR', 'B. Dacron sleeve cinched around TV annulus; discontinued due to anchor detachment in 25% of patients', 'C. Nitinol coil tethering TV annulus to IVC stent; discontinued due to stent migration complications', 'D. Two pledgets plicating posterior leaflet; discontinued due to pledget dehiscence in majority of patients', ], answer='A. Foam-filled polymer balloon spacer in RV; leaflets coaptate against it; discontinued due to 50% EROA reduction at 30 days that was not sustained at 1 year and 7/25 patients still had severe TR', explanation='FORMA (Edwards Lifesciences) consisted of a foam-filled polymer balloon spacer and a rail secured to the RV with a 6-pronged nitinol anchor. The tricuspid leaflets coaptate against this spacer to reduce regurgitation. Early studies showed 50% EROA reduction at 30 days, but this did not improve between 30 days and 1 year. 7 out of 25 patients still had severe TR. The device was discontinued and trials halted.', ) # Q20 - HETEROTOPIC TRICUSPID / TRICVALVE - OVERVIEW IMAGE story += q_block( num=20, image_fname='fig60_10_tricuspid_overview.png', img_width=8, img_caption='Fig 60.10. Overview of transcatheter tricuspid valve therapies undergoing clinical investigation: leaflet coaptation (TriClip/MitraClip, PASCAL, FORMA, Mitralix), annuloplasty repair (Cardioband, Tri-Ring), orthotopic replacement (EVOQUE, Trisol, Cardiovalve, Intrepid), and heterotopic replacement (SAPIEN XT, SAPIEN 3). (Source: DiMaio et al., Chapter 60, pp 1121-1136; adapted from Cruz-Gonzalez et al. and others, with permission from Elsevier)', img_position='before_q', stem='Looking at the classification diagram of transcatheter tricuspid valve therapies, which device uses a heterotopic (caval) approach to treat tricuspid regurgitation by implanting two self-expandable bovine pericardial valves (with polytetrafluoroethylene skirt) in the superior and inferior vena cava respectively, and is being evaluated in the TRICUS STUDY?', options=[ 'A. Tricento valve (New Valve Technology)', 'B. EVOQUE system (Edwards Lifesciences)', 'C. TricValve (P&F, Vienna)', 'D. SAPIEN XT in IVC (HOVER trial)', ], answer='C. TricValve (P&F, Vienna)', explanation='TricValve (P&F, Vienna, Austria) consists of TWO self-expandable valves made of bovine pericardium lined with PTFE skirt - one positioned in the SVC and one in the IVC (heterotopic bicaval approach). The goal is to minimize caval backflow and reduce peak systolic pressures in hepatic and renal veins. Safety/efficacy is under investigation in the TRICUS STUDY (NCT03723239, NCT04141137). Tricento anchors in IVC only. SAPIEN XT in IVC (TRICAVAL) was terminated due to dislocation. EVOQUE is orthotopic.', ) # ==== ANSWER KEY TABLE ==== story.append(PageBreak()) story.append(P("ANSWER KEY SUMMARY", title_style)) story.append(S(0.3)) ak_data = [ [Paragraph('Q', ParagraphStyle('AKH', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=colors.white, alignment=TA_CENTER)), Paragraph('Answer', ParagraphStyle('AKH2', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=colors.white, alignment=TA_CENTER)), Paragraph('Topic', ParagraphStyle('AKH3', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=colors.white, alignment=TA_CENTER)), Paragraph('Image?', ParagraphStyle('AKH4', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=colors.white, alignment=TA_CENTER))], ['1', 'A', 'MV structural components (image-based)', 'Yes'], ['2', 'B', 'Primary vs secondary MR classification', 'No'], ['3', 'C', 'Alfieri technique and MitraClip', 'No'], ['4', 'C', 'MitraClip access route and guidance', 'No'], ['5', 'B', 'EVEREST II - 30-day adverse events', 'No'], ['6', 'B', 'COAPT vs MITRA-FR - disproportionate vs proportionate MR (image)', 'Yes'], ['7', 'C', 'COAPT FDA inclusion criteria (clinical vignette)', 'No'], ['8', 'B', 'PASCAL system unique features', 'No'], ['9', 'B', 'TVT Registry real-world TEER outcomes', 'No'], ['10', 'C', 'Cardioband annuloplasty device', 'No'], ['11', 'B', 'TMVR ViV - FDA approval and outcomes', 'No'], ['12', 'C', 'TMVR devices identification (image-based)', 'Yes'], ['13', 'B', 'Tendyne device design and features', 'No'], ['14', 'B', 'MAC TMVR complications - LVOTO and embolization', 'No'], ['15', 'C', 'Tricuspid valve anatomy - septal leaflet (image-based)', 'Yes'], ['16', 'C', 'Preprocedural imaging for TV interventions (echo image)', 'Yes'], ['17', 'B', 'TriClip and TRILUMINATE trial', 'No'], ['18', 'C', 'TriAlign / Kay procedure / SCOUT trial', 'No'], ['19', 'A', 'FORMA device - mechanism and reason for discontinuation', 'No'], ['20', 'C', 'TricValve - heterotopic bicaval replacement (image-based)', 'Yes'], ] ak_table_data = [] for i, row in enumerate(ak_data): if i == 0: ak_table_data.append(row) else: ak_table_data.append([ Paragraph(row[0], ParagraphStyle('AKC', parent=styles['Normal'], fontSize=9, fontName='Helvetica', alignment=TA_CENTER)), Paragraph(row[1], ParagraphStyle('AKC2', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=colors.HexColor('#1a5c1a'), alignment=TA_CENTER)), Paragraph(row[2], ParagraphStyle('AKC3', parent=styles['Normal'], fontSize=9, fontName='Helvetica')), Paragraph(row[3], ParagraphStyle('AKC4', parent=styles['Normal'], fontSize=9, fontName='Helvetica', alignment=TA_CENTER)), ]) ak_tbl = Table(ak_table_data, colWidths=[1*cm, 2.5*cm, 11.5*cm, 3*cm]) ak_tbl.setStyle(TableStyle([ ('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1a3a5c')), ('TEXTCOLOR', (0,0), (-1,0), colors.white), ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.white, colors.HexColor('#eef4fb')]), ('FONTNAME', (0,1), (-1,-1), 'Helvetica'), ('FONTSIZE', (0,1), (-1,-1), 9), ('ALIGN', (0,0), (1,-1), 'CENTER'), ('ALIGN', (3,0), (3,-1), 'CENTER'), ('VALIGN', (0,0), (-1,-1), 'MIDDLE'), ('GRID', (0,0), (-1,-1), 0.5, colors.HexColor('#bbbbbb')), ('TOPPADDING', (0,0), (-1,-1), 4), ('BOTTOMPADDING', (0,0), (-1,-1), 4), ('LEFTPADDING', (0,0), (-1,-1), 5), ('RIGHTPADDING', (0,0), (-1,-1), 5), ])) story.append(ak_tbl) story.append(S(0.5)) story.append(HRFlowable(width="100%", thickness=1, color=colors.HexColor('#1a3a5c'), spaceAfter=8)) story.append(P("INI SS CET CVTS | Chapter 60: Transcatheter Treatment of Mitral and Tricuspid Valve Disease", subtitle_style)) story.append(P("Source: DiMaio JM, Shih E, Squiers JJ, Mack MJ. Section 2 - Adult Cardiac Surgery. Pages 1121-1136.", subtitle_style)) doc.build(story) print("SUCCESS:", OUTPUT_PATH) PYEOF python3 /home/daytona/workspace/ch60_output/generate_mcqs.py

Running Command

ls -lh /home/daytona/workspace/ch60_output/*.pdf

Both files are ready. Here are your downloads:

File 1 - High-Yield Teaching Notes

Ch60 High Yield Teaching Notes

PDF Document · PDF

File 2 - 20 MCQs (INI SS CET Format)

Ch60 MCQs INI SS CET

PDF Document · PDF

What's inside each file:

File 1 - High-Yield Teaching Notes (27 KB)

11 structured sections covering the entire chapter
Colour-coded: section headers (navy), key facts (red), sub-topics (blue)
Comparison tables: EVEREST II / COAPT / MITRA-FR trial results side by side; TMVR devices with trials; Orthotopic vs heterotopic TR devices
Real-world outcome benchmarks (TVT Registry numbers)
FDA approval timelines and criteria
20 probable exam questions in tabular format
Memory aids / mnemonics (COAPT vs MITRA-FR, Tendyne, TTCT annuloplasty, CAVI)

File 2 - 20 Single Best Answer MCQs (3.3 MB)

All 20 questions in INI SS CET single-best-answer format
5 image-based questions (Q1, Q6, Q12, Q15, Q16, Q20) using figures extracted directly from the chapter:
- Fig 60.1 - Mitral valve anatomy
- Fig 60.2 - MitraClip echocardiographic views
- Fig 60.7 - TMVR replacement devices panel
- Fig 60.8 - Tricuspid valve anatomy via right atriotomy
- Fig 60.9 - Echocardiography of TR
- Fig 60.10 - Overview of transcatheter TV therapies
All images carry full attribution to the source textbook and original publication
3 clinical vignette questions (Q2, Q5, Q7)
Detailed explanations for every question
Full answer key table at the end

This is a shared conversation. Sign in to Orris to start your own chat.